Genetic studies of LRRK2 and PINK1 in Parkinson's disease by Toft, Mathias
Thesis for the degree of philosophiae doctor
Trondheim, March 2007
Norwegian University of
Science and Technology
Faculty of Medicine
Department of Neuroscience
Mathias Toft
Genetic studies of LRRK2 and
PINK1 in Parkinson's disease
NTNU
Norwegian University of Science and Technology
Thesis for the degree of philosophiae doctor
Faculty of Medicine
Department of Neuroscience
©Mathias Toft
ISBN 978-82-471-1058-4 (printed ver.)
ISBN 978-82-471-1061-4 (electronic ver.)
ISSN 1503-8181
Theses at NTNU, 2007:48
Printed by Tapir Uttrykk
«If the clinician, as observer wishes to see things as they really
are, he must make a tabula rasa of his mind and proceed without
any preconceived notions whatever.»
Jean-Martin Charcot
3Contents
ACKNOWLEGEMENTS …………………………………………….. 5
LIST OF PAPERS ……………………………………………………. 7
SUMMARY IN ENGLISH ……………………………………………. 8
SUMMARY IN NORWEGIAN ………………………………………11
ABBREVIATIONS AND DEFINITIONS ………………………….. 14
1.   GENERAL INTRODUCTION …………………………………. 15
1.1 Historical background …………………………………………………..  15
1.2 Definitions ………………………………………………………………...  16
1.3 Epidemiology …………………………………………………………….. 19
1.4 Differential diagnosis of parkinsonism ……………………………...  19
1.5 Pathology of Parkinson’s disease ……………………………………  20
1.6 Alzheimer’s disease …………………………………………………….  22
1.7 Heredity and familial aggregation …………………………………….  22
1.8 Parkinson’s disease and the environment ………………………….  24
1.9 Genetics of familial parkinsonism ……………………………………  25
1.10 PTEN-induced kinase 1 (PINK1) ………………………………………  31
1.11 Leucine-rich repeat kinase 2 (LRRK2) ……………………………….  32
2.   AIMS OF THE STUDIES ……………………………………… 35
3.   MATERIALS ……………………………………………………. 36
3.1 Patients and control subjects …………………………………………  36
3.2 Brain tissue ……………………………………………………………….  39
4.   METHODS ……………………………………………………… 40
4.1 Molecular biology ………………………………………………………..  40
4.2 Pathology …………………………………………………………………. 42
4.3 Statistics …………………………………………………………………..  43
4.4 Ethics ………………………………………………………………………  44
45. RESULTS ………………………………………………………. 45
5.1 Review of paper I ………………………………………………………... 45
5.2 Review of paper II ………………………………………………………..  46
5.3 Review of paper III ……………………………………………………….  47
5.4 Review of paper IV ………………………………………………………  48
5.5 Review of paper V ……………………………………………………….  49
6. GENERAL DISCUSSION ……………………………………... 50
6.1 Identification and of evidence for pathogenicity of
Lrrk2 G2019S ……………………………………………………………..  50
6.2 Frequency of LRRK2 mutations ………………………………………  53
6.3 Penetrance and haplotype analyses …………………………………  55
6.4 Clinical features of LRRK2-associated parkinsonism ……………. 57
6.5 Neuropathology of LRRK2-associated parkinsonism …………….  61
6.6 LRRK2-mutations in Alzheimer’s disease and other
neurodegenerative disorders ………………………………………….  64
6.7 PINK1 mutation frequencies and clinical findings ………………... 66
6.8 PINK1 heterozygosity and parkinsonism ……………………………  68
7. CONCLUSIONS ………………………………………………... 70
8. REFERENCES …………………………………………………. 72
APPENDIX: PAPERS I - V
5Acknowledgements
The work presented in this thesis was carried out at the Department of
Neuroscience at the Faculty of Medicine, Norwegian University of Science and
Technology (NTNU) from 2003 to 2006. During this period I was receiving a
research fellowship from the Research Council of Norway as a part of the study
Genetic and metabolic studies of dementias. All genetic analyses were
performed during a two-year visit to the Department of Neuroscience, Mayo
Clinic Jacksonville.
In addition to the Research Council of Norway, a number of sources have
provided funding for the studies presented. In Norway, funding has been
obtained from Reberg’s legacy, the Norwegian Parkinson Foundation and the
Sigurd K. Thoresen Foundation. I have received personal travel grants from the
Research Council of Norway and the Unger-Vetlesen Medical Fund. Mayo
Clinic Jacksonville is a M.K. Udall Parkinson’s Disease Research Center of
Excellence and was also supported by the National Institutes of Heath.
During these years of genetic research many people have been involved, and
the work presented has truly been a collaborative effort. I would like to express
my sincere thanks to colleagues and friends who have helped, supported and
encouraged me in different ways throughout this period.
I wish to express my gratitude to the following:
· Jan Aasly. In 1998, when I was a medical student in Tübingen, he accepted
me as a visiting student to the Department of Neurology at St. Olav’s
University Hospital in Trondheim. During this and following periods of
internships and residency he and the rest of the staff of the department
introduced me to the field of neurology. His continuous encouragement and
enthusiasm for our research, and for the care of patients with Parkinson’s
disease, have been invaluable. Without him the presented studies would
not have existed.
· Matthew Farrer. He generously invited me to work in his lab at the Mayo
Clinic Jacksonville to perform the genetic studies presented in this thesis.
The two years I spent in Jacksonville were truly the most exciting years of
my life. Never have I worked in such an inspiring environment. His creativity
and enthusiasm for genetic research is remarkable, and I am grateful for
enjoying his friendship.
· Linda White. She has been project leader of the study Genetic and
metabolic studies of dementias. She has taken care of administrative
procedures and reporting related to the studies, so that I could focus my
attention to the genetic studies. Her continuous support and encouragement
has been very helpful.
· All members of the Farrer lab during the two years of my visit. They have
immense competence and experience in genetic research and were willing
6to share their knowledge with me. Special thanks to Sarah Lincoln for
teaching me numerous lab procedures and to Mary Hulihan, Jennifer
Kachergus, Owen Ross, Liza Pielsticker, and Ignacio Fernandez-Mata, who
all contributed significantly to the presented studies. I also want to thank
Stacey Melquist from the Hutton lab for contributing to Paper III.
· Sigrid Botne Sando for collecting DNA from patients with dementia, Ronny
Myhre for performing quantitative analyses of the PINK1 gene, Sylvia Nome
Kvam for help with handling blood samples, and Kristoffer Haugarvoll for
continuing some of the projects at the Mayo Clinic and for invaluable
discussions and great friendship.
· All scientists working at the Mayo Clinic Jacksonville for creating a fantastic
environment for studies of neurodegeneration. Special thanks to Dennis
Dickson for performing the pathological examinations presented in Paper
IV, and to Zbigniew Wszolek, who has studied familial parkinsonism over a
large number of years.
· All other investigators around the world who provided samples for the
studies presented.
To my family:
First I want to thank my parents for giving me the very best prerequisites to
develop, and for always supporting me with my studies and my work. I also
have to thank them and my parents in-law for valuable help in taking care of
Helene during the last period of my work with this thesis.
Finally and most of all, thanks to my ever supportive wife and best friend Tonje.
Although trying to participate in the daily activities at home, I know that I have
been constantly absent-minded. This work would never have been possible
without your patience and support, and your help in taking care of our wonderful
daughter Helene.
Oslo, September 2006.
Mathias Toft
7List of papers
Paper I
Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM,
Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K,
Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2
mutation linked to autosomal dominant parkinsonism: Evidence for a common
founder across European populations. Am J Hum Genet 2005; 76 (4): 672-680.
Paper II
Aasly JO, Toft M, Mata IF, Kachergus J, Hulihan M, White LR and Farrer M.
Clinical features of LRRK2-associated Parkinson's disease in Central Norway. Ann
Neurol 2005; 57 (5): 762-765.
Paper III
Toft M, Sando SB, Melquist M, Ross OA, White LR, Aasly JO, Farrer MJ. LRRK2
mutations are not common in Alzheimer’s disease. Mech Ageing and Development
2005; 126 (11): 1201-1205.
Paper IV
Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I,
Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW. Lrrk2 and Lewy body disease.
Ann Neurol 2006; 59 (2): 88-393.
Paper V
Toft M, Myhre R, Pielsticker L, White LR, Aasly JO, Farrer MJ. PINK1 mutation
heterozygosity and the risk for Parkinson’s disease. J Neurol Neurosurg
Psychiatry; in press.
8Summary in English
Background and objectives
Parkinson’s disease (PD) is a common neurodegenerative disorder affecting
1% of the elderly. The disease causes a significant burden of illness and cost to
society. The causes of PD have remained unknown, and the influence of
genetic factors used to be controversial. In 2004, several mutations were
identified in familial PD within two genes: PINK1 and the novel gene LRRK2.
The aims of this thesis were to further investigate genetic, clinical and
pathological aspects of these genes in PD and other neurodegenerative
disorders causing parkinsonism. Five papers based on data from studies of
these genes are included in this thesis.
Methods
· DNA from probands of families with autosomal dominant parkinsonism were
sequenced to identify novel mutations in the LRRK2 gene. After the
identification of a novel heterozygous LRRK2 mutation, we assessed the
frequency of this mutation in a total of 248 families from different
populations. We also screened samples of patients with idiopathic PD from
three populations (Norway, Ireland, and Poland). Family members of
mutation carriers were examined, and analyses of segregation, mutation
haplotypes and penetrance were performed (Paper I).
· A clinicogenetic study of PD in Central Norway was initiated several years
ago at the Department of Neurology, St. Olav’s University Hospital in
Trondheim. We screened 435 Norwegian patients diagnosed with PD and
519 control subjects from this study for the presence of seven known
LRRK2 mutations. The clinical presentation of disease was studied in
patients with mutations (Paper II).
· A series of 242 patients from a clinicogenetic study of dementia in Central
Norway (Trønderbrain) were screened for the presence of seven known
pathogenic mutations previously reported in the LRRK2 gene (Paper III).
9· We examined several brain banks for cases with clinical or pathological
features of parkinsonian disorders. DNA was obtained from frozen brain
tissue of cases with parkinsonism, other neurodegenerative disorders and
controls (total n=1584) and genotyped for the exon 41 LRRK2 g.6055G>A
(G2019S) mutation. Available medical records of mutation carriers were
reviewed and neuropathological examination was performed (Paper IV).
· Comprehensive PINK1 mutation analysis was performed in a total of 131
patients from Norway with early-onset parkinsonism (onset =50 years) or
familial late-onset PD. Mutations identified were examined in 350
Norwegian control individuals (Paper V).
Results
· We identified a novel heterozygous LRRK2 g.6055G>A mutation (G2019S).
Seven of 248 families with autosomal dominant parkinsonism (2.8%) and
six of 806 patients with idiopathic PD (0.7%) carried this mutation. All
patients with this mutation shared an ancestral haplotype, indicative of a
common founder. The mutation segregates with disease (multipoint LOD
score 2.41). Penetrance is age dependent, increasing from 17% at age 50
years to 85% at age 70 years (Paper I).
· Ten Norwegian PD patients were found to be heterozygote carriers of the
Lrrk2 G2019S mutation. The clinical features included asymmetric resting
tremor, bradykinesia, and rigidity with a good response to levodopa and
could not be distinguished from idiopathic Parkinson’s disease. No
Parkinson’s disease patient carried any of the other LRRK2 mutations
(Paper II). We did not identify LRRK2 mutations in our series of dementia
patients (Paper III).
· Lrrk2 G2019S was found in 2% (n=8) of the pathologically confirmed
PD/Lewy body disease (LBD) cases (n=405). Neuropathological
examination showed typical LBD in all cases (Paper IV).
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· Heterozygous missense mutations in PINK1 were found in three of 131
patients; homozygous or compound heterozygous mutations were not
identified. A parkinsonian phenotype, with asymmetric onset and without
atypical features, characterised these patients clinically (Paper V).
Conclusions
We identified a novel mutation in the LRRK2 gene, g.6055G>A (G2019S). This
mutation is a relatively common cause of both familial and sporadic PD, and it is
found in a number of populations from North America and Europe, including
Norway. This specific mutation is today the most prevalent known cause of PD,
but seems to be rare in other neurodegenerative disorders.
Clinically, patients with the Lrrk2 G2019S substitution present with a levodopa–
responsive parkinsonian syndrome with asymmetric resting tremor,
bradykinesia, and rigidity. Both clinically and pathologically LRRK2-associated
PD appears to be indistinguishable from idiopathic disease.
PINK1 mutations were rare in our Norwegian population, but heterozygote
mutation carriers might be at increased risk for disease.
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Summary in Norwegian
Bakgrunn og målsetninger
Parkinsons sykdom er en relativt vanlig nevrodegenerativ sykdom som rammer
1% av den eldre befolkningen. Sykdommen forårsaker vesentlige plager for
pasientene og betydelige kostnader for samfunnet. Årsakene til Parkinsons
sykdom har vært ukjente og hvorvidt genetiske faktorer medvirker har vært
omstridt. I 2004 ble mutasjoner funnet hos pasienter med familiær Parkinsons
sykdom i to gener: PINK1 og det nye genet LRRK2. Målsetningen med denne
avhandlingen var å videre undersøke genetiske, kliniske og patologiske
aspekter av disse to genene ved Parkinsons sykdom og andre
nevrodegenerative sykdommer som forårsaker parkinsonisme. Fem
vitenskapelige arbeider basert på data fra studier av disse gene inngår i
avhandlingen
Metoder
· DNA fra pasienter med autosomal dominant parkinsonisme ble sekvensert
for å identifisere nye mutasjoner i LRRK2-genet. Etter at en ny heterozygot
LRRK2-mutasjon ble funnet, undersøkte vi forekomsten av denne
mutasjonen i totalt 248 familier fra ulike land. Vi undersøkte også prøver fra
pasienter med idiopatisk Parkinsons sykdom fra tre europeiske land (Norge,
Irland og Polen). Familiemedlemmer av mutasjonsbærere ble undersøkt og
vi utførte analyser av segregasjon, haplotyper og penetranse av
mutasjonen (Artikkel I).
· For flere år siden startet en klinisk og genetisk studie av Parkinsons sykdom
i Midt-Norge ved St. Olavs Hospital i Trondheim. Vi undersøkte forekomsten
av 7 mutasjoner i LRRK2-genet hos 435 norske pasienter diagnostisert med
Parkinsons sykdom og 519 kontroller fra denne studien. Vi studerte de
kliniske kjennetegnene ved sykdommen hos mutasjonsbærere (Artikkel II).
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· 242 pasienter ble rekruttert fra en studie av demens i Midt-Norge
(Trønderbrain) og undersøkt for forekomsten av syv kjente patogene
mutasjoner som tidligere var beskrevet i LRRK2-genet (Artikkel III).
· Vi undersøkte flere hjernebanker for pasienter med kliniske eller patologiske
tegn til parkinsonistiske sykdommer. DNA fra frossent hjernevev av avdøde
pasienter med parkinsonisme, andre nevrodegenerative sykdommer og
kontroller (totalt n=1584) ble genotypet for forekomst av g.6055G>A
(G2019S) mutasjonen i ekson 41 av LRRK2-genet. Vi gjennomgikk
tilgjengelige journalopplysninger av mutasjonsbærere og utførte
nevropatologiske undersøkelser (Artikkel IV).
· Omfattende mutasjonsanalyser av PINK1-genet ble utført i totalt 131
pasienter fra Norge med parkinsonisme med sykdomsdebut =50 år eller
familiær Parkinsons sykdom. Identifiserte mutasjoner ble undersøkt i 350
norske kontroller (Artikkel V).
Resultater
· Vi identifiserte en ny heterozygot LRRK2 g.6055G>A (G2019S) mutasjon.
Syv av 248 familier med autosomal dominant parkinsonisme (2.8%) og seks
av 806 pasienter med sporadisk Parkinsons sykdom (0.7%) var bærere av
denne mutasjonen. Alle disse pasientene deler en felles haplotype, noe
som indikerer felles opphav. Mutasjonen segregerer med sykdommen i
familiene (multipoint LOD-score 2.41). Penetransen er aldersavhengig og
øker fra 17% ved 50-års alder til 85% ved 70-års alder (Artikkel I).
· Totalt ti norske pasienter med Parkinsons sykdom var heterozygote bærere
av G2019S-mutasjonen i LRRK2-genet. Klinisk presenterte sykdommen
seg med asymmetrisk hviletremor, bradykinesi og rigiditet med god effekt
av levodopa-behandling, og symptomene skilte seg ikke fra idiopatisk
Parkinsons sykdom. Ingen av pasientene var bærere av noen av de andre
undersøkte mutasjonene (Artikkel II). Vi fant ingen mutasjoner i LRRK2-
genet i vår studie av pasienter med demens (Artikkel III).
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· LRRK2 G2019S-mutasjonen ble funnet i 2% (n=8) av de patologisk
verifiserte tilfellene av Parkinsons sykdom/lewylegemesykdom (n=405).
Nevropatologisk undersøkelse viste typisk lewylegemesykdom i alle
tilfellene (Artikkel IV).
· Vi identifiserte heterozygote mutasjoner i PINK1-genet hos tre av 131
pasienter, ingen av pasientene hadde homozygote mutasjoner. Et
parkinsonistisk kliniske bilde med asymmetrisk start uten atypiske
symptomer var karakteristisk hos disse pasientene (Artikkel V).
Konklusjoner
Vi identifiserte en ny mutasjon i LRRK2-genet som fører til en G2019S-endring
av proteinstrukturen. Denne mutasjonen er en relativt vanlig årsak til både
familiær og sporadisk Parkinsons sykdom. Mutasjonen ble funnet i flere
populasjoner fra både Nord-Amerika og Europa, inkludert Norge. Mutasjonen er
i dag den vanligste kjente årsaken til Parkinsons sykdom i verden, men sjelden i
andre nevrodegenerative sykdommer. Studien viser at genetiske faktorer er
viktigere for sykdomsutviklingen enn tidligere antatt.
Klinisk presenter pasienter med Lrrk2 G2019S-mutasjonen et levodopa-
responsivt parkinsonistisk syndrom med asymmetrisk hviletremor, bradykinesi
og rigiditet. Både klinisk og patologisk synes LRRK2-assosiert Parkinsons
sykdom å være identisk med idiopatisk sykdom.
Mutasjoner i PINK1-genet er sjeldne i Norge, men heterozygote
mutasjonsbærere har muligens øket risiko for utvikling av Parkinsons sykdom.
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Abbreviations and definitions
AD Alzheimer’s disease
ALS Amyotrophic lateral sclerosis
DLB Dementia with Lewy bodies
EOP Early-onset parkinsonism
Genotype The particular set of alleles that an individual has at a given
region of the genome.
GTP Guanosine triphosphate
Haplotype A particular combination of alleles that are closely linked
on a chromosome.
LBD Lewy body disease
LOD-score Logarithm of odds-score
LRRK2 Leucine-rich repeat kinase 2
MAPT Microtubule-associated protein tau
MPTP N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MSA Multiple system atrophy
Mutation An alteration in a genome compared to some reference state. A
mutation does not have to have harmful effects.
PD Parkinson’s disease
PET Positron emission tomography
Phenotype The observable properties and characteristics of an
individual or a locus
PINK1 PTEN-induced kinase 1
Polymorphism  A region on the genome that varies between individual
members of a population.
PSP Progressive supranuclear palsy
SNP Single nucleotide polymorphism
SPECT Single photon emission computer tomography
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1. General introduction
1.1 Historical background
“Involuntary tremulous motion, with lessened muscular power, in parts
not in action and even when supported; with a propensity to bend the
trunk forward, and to pass from a walking to a running pace: the senses
and intellects being uninjured.”
This was the definition of paralysis agitans given by James Parkinson (1755-
1824) in his classical publication An essay on the shaking palsy (1). Parkinson
noted the occurrence of tremor, alterations of gait
and posture, hypophonia, dysgraphia, and sialorrhea.
For decades Parkinson’s work went largely
unrecognized until Jean-Martin Charcot (Figure 1)
further defined the syndrome by adding rigidity to the
symptoms, and in tribute named the disorder maladie
de Parkinson (Parkinson’s disease, PD). In his later
years, Charcot was interested in the idea of disorders
running in families, and his students also studied
the heritability of PD.
For a long time PD remained an untreatable disorder with devastating
consequences for the patients. The key event leading to the development of
effective treatment was the discovery by Ehringer and Hornykiewicz of striatal
dopamine deficiency in brains of PD patients (2). For the first time levels of a
specific neurotransmitter correlated with a disease of the brain.
Subsequently, levodopa was tried in PD patients, but throughout most of the
1960s the results were inconsistent. In 1967, questions about the effectiveness
of levodopa in PD were finally set aside when Cotzias and colleagues reported
dramatic improvement in PD patients with oral administration of levodopa in
increasing amounts over long periods (3).
Figure 1. Jean-Martin Charcot
(1825 – 1893)
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Dopamine replacement therapy allows remarkable long-term symptomatic
control over the motor features of PD. Other existing treatments, including deep
brain surgery, can control the motor complications associated with chronic
levodopa treatment. However, the patients’ quality of life continues to
deteriorate as a consequence of the so-called “non-dopaminergic” clinical
manifestations: gait and equilibrium difficulties, autonomic dysfunction,
depression and cognitive impairment (4).
Thus, the present challenge is to increase the biological understanding of the
neurodegenerative process, so that new therapies slowing and halting disease
progression can be developed. Studies of genetic defects causing
parkinsonism, and of patients affected by these genetic disorders, have
identified key proteins and pathways involved in neuronal cell death. Genetic
insights have provided the rationale for new strategies for prevention and
therapy. The primary aim of this thesis was to identify genetic causes of
Parkinson’s disease and to study the clinical and pathological features
associated with it.
1.2 Definitions
Parkinsonism
Parkinsonism is a clinical syndrome characterized by the cardinal motor signs:
bradykinesia, resting tremor, muscle rigidity, and postural instability. A large
number of neurodegenerative and other disorders of the central nervous system
can present with parkinsonism.
Parkinson’s disease
A diagnosis of PD is based on the clinical identification of some combination of
the mentioned cardinal motor signs, asymmetry of disease onset, response
upon dopaminergic treatment, and absence of atypical symptoms. In addition, a
disease causing parkinsonism and secondary causes of parkinsonism should
be absent.
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There is no definite biomarker for PD. Routine blood tests, structural imaging of
the central nervous system and other paraclinical tests are mainly used to
exclude another etiology for the parkinsonian syndrome. Functional imaging,
such as SPECT and PET, can directly assess neurotransmitter activity in the
nigrostriatal dopaminergic system. Most causes of parkinsonism are associated
with reduced striatal tracer uptake compared with normal aging. PD can, to
some extent, be differentiated from other causes of parkinsonism because it is
associated with particularly low levels of tracer uptake in the putamen. PD has
however so far remained a clinical diagnosis.
Several groups have therefore proposed diagnostic criteria for a diagnosis of
PD, to reliably distinguish PD from other conditions with parkinsonian features.
In Papers I, II and V, the criteria proposed by Gelb and colleagues were used.
Three levels of diagnostic confidence are differentiated: definite, probable and
possible. The diagnoses of possible and probable PD are based on clinical
criteria alone, whereas neuropathological confirmation is required for the
diagnosis of definite PD (Table 1) (5).
Familial and sporadic PD
In this thesis, the term PD describes any patient fulfilling these diagnostic
criteria, including patients with a family history of parkinsonism. In the literature,
patients with a clinical syndrome indistinguishable from typical PD caused by
known genetic mutations have been referred to using the terms PD and
parkinsonism. It could be argued that patients affected by parkinsonism with a
known etiology should not be referred to as having PD, and that this term
should be reserved for idiopathic cases. However, from a clinical point of view
these patients can fulfill all proposed criteria. Patients with an unknown cause of
PD are referred to as having idiopathic PD.
Sporadic PD is in this thesis defined as PD in a patient without any first or
second degree relative having a known diagnosis of PD.
Familial PD is defined as PD in a patient with at least one first or second degree
relative with PD.
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Table 1. Diagnostic criteria for PD (from Gelb et al., ref. 5)
Grouping of clinical features according to diagnostic utility
Group A features: characteristic of PD
   Resting tremor
   Bradykinesia
   Rigidity
   Asymmetric onset
Group B features: suggestive of alternative diagnoses
   Features unusual early in the clinical course
     - Prominent postural instability
     - Freezing phenomena
     - Hallucinations
     - Dementia preceding motor symptoms or in the first year
   Supranuclear gaze palsy or slowing of vertical saccades
   Severe, symptomatic dysautonomia
   Documentation of a condition known to produce parkinsonism plausibly connected to the
   symptoms
Proposed diagnostic criteria for Parkinson’s disease
Criteria for POSSIBLE diagnosis of PD
   - At least 2 of 4 features in Group A, at least one of these is tremor or bradykinesia
   - None of the features in Group B (or symptoms for less than 3 years)
   - Response to dopaminergic treatment or not had adequate trial
Criteria for PROBABLE diagnosis of PD
   - At least 3 of 4 features in Group A
   - None of the features in Group B
   - Response to dopaminergic treatment
Criteria for DEFINITE diagnosis of PD
   - All criteria for POSSIBLE PD are met
   - Histopathological confirmation
Autosomal dominant and recessive PD
Autosomal dominant inheritance refers to genetic conditions that occur when
mutations are present in one allele of a given gene. Families with two or more
members affected by PD in at least two consecutive generations are in Paper I
considered to be consistent with an autosomal dominant pattern of inheritance.
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Autosomal recessive inheritance refers to genetic conditions that occur only
when mutations are present in both alleles of a given gene. In Paper V, 20
patients with a family history consistent with recessive inheritance were
included. This was broadly defined by the presence of parkinsonism in siblings
and/or first degree cousins, without evidence of affected parents or offspring.
Early-onset parkinsonism
In this thesis a patient affected by parkinsonism at 50 years of age or earlier is
considered to have early-onset parkinsonism (EOP).
1.3 Epidemiology
The prevalence of PD has been estimated in several studies, and most of them
have found prevalence figures between 100 and 150 per 100.000 inhabitants
(6). In a community study from the County of Rogaland in Norway the total age-
adjusted prevalence rate was 102 per 100,000. Men are somewhat more likely
to develop the disorder. In the mentioned study, sex specific age-adjusted
prevalence rates were 121 per 100,000 men and 90 per 100,000 women (6).
Mean age of onset is 58 to 62 years in most reports. The frequency of PD
increases with age, which is the strongest risk factor disease development . In a
study from Rotterdam, PD affected more than 1% of the population older than
55 years of age (7). Hence, PD is a prevalent disease among the elderly.
1.4 Differential diagnosis of parkinsonism
The most common cause of parkinsonism is PD, but parkinsonism is also
frequent in a large number of other neurodegenerative disorders (Table 2).
Symptomatic parkinsonism occurs secondary to the use of drugs with
antidopaminergic effects, and also in vascular, toxic, metabolic, infectious, and
post-infectious disorders.
The clinical diagnostic accuracy of PD can be improved with the use of
published and validated criteria (5). However, because of the overlapping
clinical features of parkinsonian disorders, histopathologic confirmation is still
required for the definite diagnosis of PD and other parkinsonian disorders (8, 9).
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Table 2. Neurodegenerative disorders manifesting parkinsonism
Synucleinopathies
Lewy body disorders
Parkinson’s disease
Dementia with Lewy bodies
Pure autonomic failure
Glial inclusion body disorders
Multiple system atrophy
Other synucleinopathies
Pantothenate kinase associated neurodegeneration
Pallidonigroluysian atrophy
Tauopathies
Progessive supranuclear palsy
Corticobasal degeneration
Frontotemporal dementia with parkinsonism
Alzheimer’s disease
Postencephalitic parkinsonism
Guam amyotrophic lateral sclerosis/parkinsonism dementia complex
Other neurodegenerations
Spinocerebellar ataxia 2
Spinocerebellar ataxia 3
Dentatopallidoluysian dystrophy
X-linked dystonia-parkinsonism
1.5 Pathology of Parkinson’s disease
The principal neuropathological changes in PD are
depigmentation, loss of cells and gliosis in the
substantia nigra, with formation of Lewy neuritis and
Lewy bodies within many of the remaining neurons
(Figure 2). The nigral damage is accompanied by
pathology in the locus ceruleus, dorsal motor nucleus
of the vagus nerve, nucleus basalis of Meynert, and
the ventral tegmental area of the midbrian as well as
other subcortical nuclei. In more advanced stages
lesions reach the neocortex (9).
Figure 2. A Lewy body
within a neuron in the
substantia nigra.
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The pathological term Lewy body disease (LBD) includes the clinical diagnoses
PD with and without dementia, as well as dementia with Lewy bodies (DLB).
DLB exhibits a clinical phenotype apparently different from PD, but the
morphology of the Lewy neurites and Lewy bodies, the characteristics of the
vulnerable neuronal types, and the distribution of affected subcortical nuclei and
cortical areas closely overlap with those of PD (10). Brainstem predominant,
limbic (transitional) and neocortical LBD are distinguished on neuropathological
examination.
The incidence of Lewy bodies in the brains of asymptomatic individuals
increases with advancing age. Lewy bodies also occur in 10 to 40% of
individuals with AD and in some other neurodegenerative disorders (5). This
indicates that Lewy bodies might not represent specific underlying pathological
mechanisms. Similarly, many cases of PD with Lewy bodies have concurrent
pathologic findings typical for AD.
Lewy bodies, first described by Friedrich Heinrich Lewy in 1912, are
eosinophilic cytoplasmic fibrillar aggregates containing a-synuclein and various
other proteins and are found in affected brain regions. a-synuclein aggregation
is a pathologic feature common to sporadic and inherited forms of PD, as well
as to other neurodegenerative disorders, and these disorders have collectively
been called synucleinopathies (Table 2).
Other forms of parkinsonism are characterized neuropathologically by
prominent intracellular accumulations of abnormal filaments of the microtubule-
associated protein tau, known collectively as neurodegenerative tauopathies
(Table 2). Mutations in this gene (MAPT) are found in families with
frontotemporal dementia with parkinsonism (11). Common variants in the MAPT
gene are associated with progressive supranuclear palsy (PSP) (12), and
possibly also with corticobasal degeneration (13). More intriguingly, in a study
not included in this thesis we found an association between MAPT haplotypes
and PD, demonstrating a possible link between PD and other causes of
parkinsonism (14).
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1.5 Alzheimer’s disease
Alzheimer's disease (AD) is the most common cause of dementia in the elderly.
It is characterized clinically by a gradual onset and progression of memory loss.
Parkinsonism can be a part of the clinical presentation. At postmortem
examination there is presence of two types of neuropathological inclusions:
neurofibrillary tangles and senile plaques. Neurofibrillary tangles are composed
of paired helical filaments of hyperphosphorylated tau protein, whereas the
main proteinaceous component of senile plaques is ß- amyloid.
Clinical diagnostic criteria have been developed, increasing the accuracy of the
diagnosis relative to neuropathologic examination. The most frequently used
criteria for the diagnosis of AD are those of the NINCDS-ADRDA (15). These
criteria classify AD based on degree of certainty and whether AD is associated
with other disease processes.
Currently, there are four genes that are implicated in risk for familial AD.
Mutations in the genes that encode ß- amyloid precursor protein, presenilin-1,
and presenilin-2 cause the rare early-onset form of familial AD. The fourth gene,
which encodes apolipoprotein E, is a major risk factor in both early-onset (onset
before 65 years) and late-onset (onset after 65 years) AD. However, these four
genes together may account for less than half the genetic variance in AD, and
possibly several other genes remain to be identified (16).
1.7 Heredity and familial aggregation
Leroux and Lhirondel, two of Charcot’s students at the Hôpital de la Salpêtrière
in Paris, were probably the first to record a familial component to PD, stating
that “a true cause of paralysis agitans, and maybe the only true cause, is
heredity” (17). Several other reports in early European literature also described
hereditary parkinsonism (18).
Henry Mjönes, who studied familial parkinsonism in Sweden in the 1940’s, was
the first to use a systematic genetic-statistical approach. In his thesis, he
proposed that PD was inherited in an autosomal dominant fashion with reduced
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penetrance (19) (Figure 3). Although
other reports provided additional
evidence that genetic factors may be
important in the genesis of PD (20), the
role of genetics remained controversial.
A family history of PD is second only to
age as a predictor of increased risk of
the disease (21, 22). Numerous
studies have investigated familial
aggregation of PD and the majority
has reported higher frequency of PD
among relatives of probands
compared to relatives of control
individuals. The estimate of relative risk has varied from 2.3 to 14.6 (23). A
recent study, which used a family study method assessing relatives individually,
confirmed that relatives of patients with younger disease onset (<67 years) were
at increased risk (24).
Concordance rates of disease in monozygotic and dizygotic twin pairs have
traditionally been used to measure the genetic contribution to any condition.
Large cross-sectional twin studies have identified significant differences in
concordance rates between monozygotic and dizygotic twins in early-onset PD
(age at onset <50 years), but not in late-onset disease (25, 26). However, even
these large and well-designed twin studies are probably underpowered to detect
incompletely penetrant mutations (27).
Longitudinal twin studies using 18F-dopa PET have been used to highlight
clinically pre-symptomatic dopaminergic loss. Results suggest 75% disease
concordance in monozygotic twins, versus 22% concordance in dizygotic pairs,
regardless of age at onset (28). Based on the combination of clinical data and
genealogical records, significant clustering for late onset PD was shown in
Iceland with familial aggregation extending beyond the nuclear family (29).
Figure 3. The pedigree shown is one of
the families studied by Henry Mjönes
and is an example of the proposed
autosomal dominant inheritance model.
Individuals affected by PD are denoted
with a blackened circle.
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In total, these data suggest that the contribution of genetics to parkinsonism
may be greater than previously appreciated. On the other hand, most patients
do not have a clear family history of disease, probably because either the
causative genes have low penetrance, or the disorder is a result of a
combination of genetic predisposition, environmental exposure and stochastic
factors.
1.8 Parkinson’s disease and the environment
Environmental factors were long thought to be the predominant cause of PD
(30). The epidemic of encephalitis lethargica in the beginning of the 20th century
left large numbers of survivors with neurologic sequelae, including a form of
progressive parkinsonism. Subsequently, infectious agents were suspected to
be environmental factors causing PD (31). However, PD does not generally
present in clusters or epidemics, making this hypothesis an unlikely explanation
for the majority of cases.
In the early 1980s, drug addicts mistakenly synthesized and injected
themselves with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and
developed a levodopa-responsive parkinsonian syndrome (32). MPTP causes
selective degeneration of the nigrostriatal pathway by inhibition of mitochondrial
complex I (33), and following this discovery other toxins affecting the
mitochondrion, such as epoxymycin and rotenone, were studied as potential
environmental causes of PD.
A large number of environmental agents ranging from rural living, industrial
toxins and heavy metals have been examined, although no conclusive link has
yet been identified (30). Smoking has an inverse association with PD, whereas
studies of other environmental agents have been consistently inconsistent. In
conclusion, no environmental factor has so far been established as definitively
associated with PD.
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1.9  Genetics of familial parkinsonism
A major breakthrough in recent years has been the mapping of a number of loci
linked to familial parkinsonism and the cloning of several genes causing
monogenic forms of the syndrome (Table 3). In addition, at least 5 other genetic
disorders have phenotypic overlap with PD (Table 4). These diseases should be
thought of separately from the PARK loci, as they rarely present clinically with
parkinsonism only.
Table 3. Familial parkinsonism with reported mutations/loci
Locus Chromosome Gene Clinical phenotype
Autosomal dominant
PARK1/4 4q21 a-synuclein Early onset PD and DLB
PARK3 2p13 Unknown PD
PARK5 4p14 UCH-L1 PD
PARK8 12q12 LRRK2 Predominantly PD; also dementia,
PSP-like and ALS
Autosomal recessive
PARK2 6q25-27 Parkin Early-onset PD
PARK6 1p35-36 PINK1 Early-onset PD
PARK7 1p36 DJ-1 Early-onset PD
Unknown
PARK10 1p32 Unknown PD
PARK11 2q36-37 Unknown PD
Despite the discovery of genetic defects in familial parkinsonism, the role of
genetics in sporadic late-onset PD has remained controversial. This controversy
has not only been caused by the relatively low number of patients carrying
known mutations in these genes, but also by the clinical and neuropathologic
differences between sporadic PD and the hereditary forms of parkinsonism.
However, with the increasing number of patients identified with a genetic form of
PD, this view is gradually changing.
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Table 4. Genetic diseases with parkinsonism as part of the clinical
spectrum
Disease Chromosome Gene Clinical phenotype
SCA2 12q23-24 ATXN2 Ataxia, parkinsonism
SCA3 14q32 ATXN3 Ataxia, parkinsonism
FTDP-17 17q21-22 MAPT, PGRN FTD, PD, PSP, CBD, ALS
XDP (DYT3) Xp13.1 Unknown Dystonia-parkinsonism
RDP (DYT12) 19q13 ATP1A3 Dystonia-parkinsonism
ATP1A3, Na+/K+ ATPase alpha 3 polypeptide; ATXN2, Ataxin 2; ATXN3, Ataxin 3; CBD,
Corticobasal degeneration; FTP-17, Frontotemporal dementia linked to chromosome 17; MAPT,
Microtubule-associated protein tau; PGRN, Progranulin; RDP, Rapid-onset dystonia-parkinsonism;
SCA, Spinocerebellar ataxia; XDP, X-linked dystonia parkinsonism.
In the following section, the previously identified genes in familial parkinsonism
will be briefly reviewed.
a-synuclein (PARK1)
In 1996, the first locus for autosomal dominantly inherited parkinsonism was
mapped to chromosome 4q21-q23 in the Contursi kindred, a large kindred of
Italian descent (34). Subsequently, a missense mutation in the a-synuclein
gene leading to an A53T amino acid substitution was identified in several
families (35). Confirmation of a-synuclein’s involvement in disease was
provided when a second pathogenic mutation, A30P, was identified in a small
German family (36). Missense mutations in the a-synuclein gene are rare (37).
Numerous patients from families with parkinsonism have now been sequenced
(38); only one additional pathogenic mutation (E46K) has been identified in a
Basque family (39).
Clinically, members of the Contursi kindred (A53T) showed typical features of
PD, including the cardinal motor features and a positive response to levodopa
treatment (40). Other patients with the A53T substitution have presented a
broader phenotype with central hypoventilation, orthostatic hypotension and
myoclonus (41). Compared with idiopathic PD, disease onset in mutation
carriers occurs relatively early in life, and the course from disease onset to
death is rapid. Clinical symptoms of patients with A30P closely resembles
27
idiopathic PD (42). Carriers of the E46K mutation present severe parkinsonism
with development of dementia, hallucinations and fluctuations of consciousness
(39).
Genomic multiplications of the complete a-synuclein gene have also been
linked to familial PD. Genomic triplications of the locus were identified in the
large Spellman-Muenter kindred and in a Swedish-American family (43, 44).
Subsequently, three French families have been identified with duplications of
the normal a-synuclein gene (45, 46). A large number of PD patients have now
been screened for multiplications, demonstrating that also this is a rare disease
mechanism (47-49).
A direct relationship between a-synuclein gene dosage, expression and the age
of disease onset, progression and phenotypic severity has been observed (44).
Genomic triplication of the gene causes a rapidly progressive form of
parkinsonism characterized by young age at onset, weight loss, followed later
by dementia and early death (18, 43). In contrast, the clinical phenotype of
families with a duplication of the wild-type gene resembles idiopathic PD with
late age at onset, slower disease progression and without early development of
dementia (45, 46).
A possible role of a-synuclein in the pathogenesis of sporadic PD was suggested
after the finding of the a-synuclein protein as a major component of Lewy bodies
(50). Antibodies raised against a-synuclein stain Lewy body inclusions in surviving
neurons of the substantia nigra in both familial and sporadic PD.
The three substitutions alter the properties of the a-synuclein protein, leading to
an increased propensity of the protein to aggregate (51, 52). This process is
thought to be a crucial step in formation of the Lewy bodies, and therefore in the
molecular pathogenesis of the disease. The presence of a-synuclein containing
Lewy bodies in the absence of coding mutations in sporadic PD suggests that
other a-synuclein modifications or additional interacting genes may be
contributing to sporadic PD.
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Parkin (PARK2)
Mutations in the parkin gene were first described in consanguineous Japanese
families with autosomal recessive juvenile parkinsonism (53). Numerous
mutations (>100) including exonic deletions, insertions, and point mutations
have been observed in patients of all ethnic backgrounds (reviewed by (54).
Parkin-associated early-onset PD (<45 years) is relatively common. In a study
of individuals from different European populations, this gene caused 49% of
familial early-onset PD and 18% of sporadic early-onset disease (55). Similar
mutation frequencies have also been found in several other studies (56, 57).
However, the genetic epidemiology of parkin is complex. The frequency of
mutations in sporadic patients decreases significantly with increasing age at
onset, and parkin mutations are rare in patients with late-onset PD (>50 years)
(55, 58). The role of heterozygous mutations as risk factor for PD is still unclear,
as the results in the literature are contradictory. Evidence for dominant parkin-
proven familial disease has been published (59, 60), and one study found
reduced 18F-dopa uptake in clinically asymptomatic carriers in a family with
parkin mutations (61). Intriguingly, mutation carriers in other families do not
show signs of parkinsonism (62), and in North American community based late-
onset PD, the carrier frequency of heterozygous parkin mutations is ~3%,
similar to that in controls (63).
The clinical phenotype most commonly resembles sporadic disease, but a
number of clinical features are associated with parkin disease. Symmetrical
involvement, dystonia and hyperreflexia at onset is more common (55, 64). The
disease course seems to be relatively benign with slow disease progression,
sleep benefit and good response to levodopa, but complicated with early motor
fluctuations and development of dyskinesias (65). Pyramidal signs, cerebellar
features and psychiatric disease have been reported, though dementia seems
to be rare (64).
Neuropathological studies of patients with parkin mutations with homozygous
exonic deletions show selective cell loss of the nigrostriatal tract and locus
ceruleus, with a remarkable absence of Lewy bodies (66, 67). In contrast, Lewy
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body pathology or neurofibrillary tangles have been identified post-mortem in
compound heterozygous cases with possible partial parkin function (60, 68).
Cell loss in the substantia nigra in parkin-associated PD appears to be caused
by a loss of function of the parkin protein.  Functionally, the parkin protein is a
member of a family of E3 protein ligases responsible for the transfer of activated
ubiquitin molecules to a substrate (69). Numerous potential substrates have
been nominated (54). Depending on the mutation, mutants have either reduced
or absent enzymatic function, which may help explain the conflicting data on
disease susceptibility and outcome in carriers (70). Polymeric ubiquination of a
protein typically acts as a signal for its subsequent proteasomal degradation. In
this process waste, damaged or misfolded proteins are tagged for destruction
by the proteasome. There is also some evidence indicating that inhibition of the
ubiquitin-proteasome might also be responsible for degeneration of the
nigrostriatal pathway in idiopathic PD (71).
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1; PARK 5)
By sequencing of 72 families with PD, Leroy and colleagues identified a single
missense mutation g.277C>G (I93M) in the UCH-L1 gene in two German
siblings (72). In both patients the clinical syndrome was typical for PD, with
disease onset at a mean age of 50 years, and a beneficial response to
levodopa replacement therapy. There are no radiological or neuropathological
reports available on this family. The significance of these findings is however
uncertain, as no other families with mutations in this gene have been found to
date (73, 74). A common coding polymorphism in the UCH-L1 gene leading to a
S18Y substitution has been identified; the Y18 variant was reported to be
inversely associated with PD in a dose-dependent manner (75). However, this
association has been questioned by a recent case-control study and meta-
analysis (76).
UCH-L1 is one of the most abundant proteins in the brain and
immunofluorescence studies of Lewy bodies are positive for UCH-L1 protein,
which possibly implicates it either directly or indirectly with the development of
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PD (77). The protein is also functionally involved in the ubiquitin-dependent
proteolytic pathway; hence UCH-L1 is a good candidate gene for PD.
DJ-1 (PARK7)
In 2003, mutations in the DJ-1 gene were identified in two consanguineous
families with early-onset autosomal-recessive parkinsonism originating from the
Netherlands and Italy (78). Pathogenic DJ-1 mutations in early-onset PD are
rare and the mutation frequency in early-onset PD has been estimated at
approximately 1% (79). Several other studies have failed to identify DJ-1
alterations in PD patients originating from different populations (80-82).
Clinically, patients with DJ-1 mutations have asymmetric symptoms with slow
progression and sustained response to levodopa treatment. Age of onset is
typically between 20 and 40 years. Focal dystonia and psychiatric co-morbidity
have been reported (83, 84). The neuropathology associated with DJ-1
parkinsonism is still unknown. Functional neuroimaging of DJ-1 homozygous
mutation carriers showed a decreased 18F-dopa uptake concordant with typical
PD. Clinically unaffected heterozygous mutation carriers had normal 18F-dopa
metabolism. This indicates that heterozygosity is not a risk factor for PD and
that a nearly complete loss of DJ-1 protein function is necessary to cause
disease (85).
The function of DJ-1 is unknown, but it is an abundant protein dimer in brain,
mainly expressed in astrocytes (86). An acidic isoform accumulates after
oxidative stress, indicating that DJ-1 limits cellular toxicity (87). Oxidative
conditions induce a modification of DJ-1, supporting the hypothesis that DJ-1 is
an oxidative stress sensor within cells (88). Studies of the dopaminergic system
in DJ-1-deficient mice have suggested an essential role for DJ-1 in
dopaminergic physiology and D2-receptor mediated functions (89). The DJ-1
protein is localized to mitochondria, at least in a proportion of transfected cells,
suggesting that DJ-1 can be targeted to the mitochondrion under certain
conditions and protect against neuronal death (78, 90). Thus, DJ-1 further
indicates a link between mitochondrial impairment and the pathogenesis of
Parkinson’s disease.
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1.6 PTEN-induced kinase 1 (PINK1)
In 2004 Valente and colleagues identified mutations in the PTEN-induced
kinase 1 (PINK1) gene in three families with autosomal recessive EOP
previously linked to the PARK6 locus on chromosome 1p35-36 (91). One
homozygous truncating mutation was found in two consanguineous Italian
families, whereas a homozygote missense mutation at a highly conserved
amino acid was found in a third consanguineous family of Spanish origin.
Other PINK1 mutations have now been identified in families from different
European, Asian, African and North American populations (92-95). Ibanez and
colleagues studied 177 autosomal recessive PD families with ages at onset =60
years and found homozygous or compound heterozygous mutations in seven
families. This study suggested that PINK1 is the second most frequent
causative gene in EOP (96). PINK1 mutations have also been found as a
relatively rare cause of sporadic early-onset PD (97-99).
The clinical picture of PINK1 associated disease was first reported to be
characterized by a typical parkinsonian phenotype with asymmetric onset and
rare occurrence of atypical features (97). Slow progression of disease, early
onset of levodopa-induced dyskinesias and sustained response to
dopaminergic treatment is common (100). PINK1 mutations cause PD with early
onset, and patients reported have mainly presented with symptoms before the
age of 50. The median age at onset has been reported to be around 35 years
(96).
Recent studies have indicated that the phenotype associated with PINK1
mutations might be broader than first reported. Compared to patients without
mutations in PINK1 or parkin, PINK1 mutation carriers more frequently
presented with dystonia at onset and hyperreflexia in the lower limbs. In
addition, psychiatric disturbances has been found in a number of patients (92,
94, 96).
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The neuropathological substrate of PINK1 associated PD is unknown, as no
reports have been published. However, a 18F-dopa PET study showed a
different pattern of nigrostriatal dopaminergic dysfunction in PARK6-linked PD
than idiopathic disease, indicating different neuropathological features (101).
The PINK1 gene has 8 exons and encodes a serine/threonine kinase localized
to the mitochondrion. Little is known about protein function, but it may protect
neurons from stress-induced mitochondrial dysfunction (91). Specific mutations
have been shown to impair protein folding/half-life and kinase activity ex vivo
(102). Recent reports have indicated genetic interactions between PINK1 and
parkin. Loss of PINK1 in Drosophila melanogaster models lead to defects in
mitochondrial function with muscle and dopaminergic neuron degeneration that
can be rescued by parkin (103-105). Hence, the two genes appear to function in
a common pathway.
1.11 Leucine-rich repeat kinase 2 (LRRK2)
In 2002, Funayama and colleagues performed a genome-wide linkage analysis
of a Japanese family with autosomal dominant parkinsonism (106). In this
family, also known as the Sagamihara kindred, members presented with clinical
features that may not be distinguished from sporadic late-onset PD (107). The
clinical symptoms responded well to levodopa, and mean age at symptom onset
was 51 years. Neuropathologic examinations in 4 members of the kindred
showed pure nigral degeneration without any identified Lewy bodies.
Parametric 2-point linkage analysis generated a highly significant logarithm of
odds (LOD) score of 4.32 at the marker D12S345. Haplotype analysis of
markers on chromosome 12 shared by affected family members defined the
disease-associated haplotype to a relatively large 13.6-cM region located to
12p11-q13 (106). The chromosome 12 locus differed from previously reported
regions linked to familial parkinsonism and was assigned the symbol PARK8.
After identification of the PARK8 locus, linkage to this region was confirmed in a
study of autosomal dominant parkinsonism in 21 families originating from
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Europe and North America (108). Based on analysis of the two kindreds with
the highest LOD scores in this study (Family A and Family D), the most likely
disease gene location was a 3.2-cM region on chromosome 12q12. A study of 4
Basque families also found evidence for linkage of autosomal dominant PD to
the PARK8 locus, with a maximum 2-point LOD score of 3.21 (109). Combined,
these studies provided evidence that the PARK8 locus is responsible for a
subset of families with autosomal dominant parkinsonism and suggested that
the locus may be relatively common and occur in patients from different
populations.
The existence of a gene within the PARK8 locus associated with familial
parkinsonism was finally established when the two groups identified a total of
seven mutations in a novel gene, which was assigned the name leucine-rich
repeat kinase 2 (LRRK2) (110, 111). All mutations were located within the
predicted functional domains of the novel protein and segregated with disease
within the families. Clinically, most patients in these studies presented with late-
onset Parkinson’s disease. However, neuropathological examinations
demonstrated brainstem dopaminergic degeneration accompanied by strikingly
diverse pathologies.
The LRRK2 gene is located close to the centromere on the long arm of
chromosome 12, and the gene was not studied until the identification of
pathogenic mutations in parkinsonian kindreds. To establish the complete cDNA
sequence, the LRRK2 gene was amplified from human brain cDNA using
overlapping primers predicted by homology searches. The gene spans a
genomic region of 144 Kb, with a total of 51 exons encoding a 2,527–amino
acid protein (Figure 4) (111).
Using Northern blots and real-time reverse transcriptase–polymerase chain
reaction methods, expression analyses have shown that the LRRK2 gene is
expressed at low levels throughout the adult human brain, with slightly higher
expression in putamen and substantia nigra than in other brain regions. Of other
tissues examined, the gene expression is highest in lungs (110, 111).
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The function of the Lrrk2 protein is still largely unkown. However, in silico
predictions and homology searches of similar proteins in other species indicate
that Lrrk2 is a member of the recently defined Roco protein family. In humans,
mice, and rats, members of the Roco family have five conserved functional
domains (Fig. 1) (112). These multidomain proteins have been found in species
ranging from mammals to metazoans and exhibit various functions.
The Lrrk2 protein has a large N- terminus ending with ankyrin and leucine-rich
repeats (LRR) consisting of 12 strands of a 22– to 28–amino acid motif
presented in a tandem array. The Roc (for Ras of complex proteins) domain
contains a GTPase-like domain with homology to all four members of the
GTPase superfamily. GTPases are small proteins that regulate a wide array of
cellular processes, such as signaling, differentiation, and growth through
binding and hydrolysis of guanosine triphosphate (GTP) (112).
All Roco proteins contain a novel COR (C-terminal of Roc) domain, which is
about 300 to 400 amino acids long. The function of this domain is currently
unknown. A kinase domain with a catalytic core common to serine and
threonine and to tyrosine protein kinases is always present in this protein family.
The kinase domain belongs to the MAPKKK subfamily of kinases. There is a
WD40 repeat domain at the carboxylate terminus.
Figure 4. Chromosome 12 and the structure of the LRRK2 gene and the Lrrk2 protein. A) The
PARK8 locus is located on chromosome 12q12. B) The LRRK2 gene has 51 exons; the localization
of mutations with proven pathogenicity is noted. C) Pathogenic mutations are located within the
functional domains. COR, C-terminal of Roc; LRR, leucine-rich repeat; MAPKKK, mitogen-activated
protein kinase kinase kinase; ROC, Ras in complex proteins; WD40, WD40 repeats.
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2. Aims of the studies
Paper I
- Sequence the LRRK2 gene in families previously linked to the PARK8 locus
to identify novel mutations.
- After the identification of a novel G2019S mutation, we wanted to examine
the mutation frequency in autosomal dominant and sporadic Parkinson’s
disease.
- Examine the segregation pattern and penetrance of this mutation within
families.
Paper II
- Examine the presence of LRRK2 mutations in a clinic-based sample of PD
from Central Norway.
- Describe the clinical features of LRRK2-associated PD.
Paper III
- Examine the frequency of LRRK2 mutations in neurodegenerative disorders
causing dementia in a sample from Central Norway.
Paper IV
- Investigate the frequency of the Lrrk2 G2019S substitution in a brain bank
series of cases with clinical or pathological features of parkinsonism.
- Describe the pathology associated with disease in identified cases with a
LRRK2 mutation.
Paper V
- Examine the role of mutations in the PINK1 gene in a Norwegian series of
early-onset parkinsonism and familial late-onset PD.   
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3. Materials
3.1 Patients and control subjects
Four of the papers in this thesis have used DNA and clinical information
obtained from clinical samples of patients with neurodegenerative disorders:
PD – Trondheim
For Papers I,II and V we used a clinic-based series from Central Norway.
Inclusion of patients with PD into this study has been performed since 1998.
Four hundred and thirty-five patients have been clinically examined and are
followed longitudinally by one neurologist (Jan O. Aasly) at the outpatient clinics
of three hospitals in Central Norway (St. Olav’s Hospital, Trondheim; Ålesund
Hospital, Ålesund; and Helgeland Hospital in Mosjøen). A total of 403 patients
were referred from general practitioners and other hospitals; a further 32
patients with a family history of PD were self-referred. This was in response to a
local newsletter by the National Norwegian PD Association. Patients with a
family history of PD were asked to inform their family members of this research.
Any family members who expressed an interest in participating were invited to
take part.
A full history, including a family history and neurological examination, was
completed for each patient. Clinical criteria for a diagnosis of PD were
consistent with possible or probable PD as proposed by Gelb and colleagues
(5). Patients demonstrating severe autonomic dysfunction, poor response upon
dopaminergic treatment or early dementia were not included. Clinical judgment
and the Mini Mental State Examination (MMSE) were used to assess cognitive
function. All patients underwent routine laboratory blood testing, and blood
samples for DNA extraction and genetic testing were obtained.
Five hundred and nineteen control individuals without signs of a movement
disorder were recruited from the same region of Central Norway. Characteristics
of patients and controls included in the study are listed in Table 5.
.
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Table 5. Demographic information on patients with PD included in Paper I,
II and V.
Groups n Gender (%) Disease
onset (years)
Range
(years)
Age at last
exam
PD patients 435 174 F (40) 60.3 ± 10.9 33-88 70.2 ± 9.3
261 M (60) 57.6 ± 10.9 28-80 66.3 ±10.8
Controls 519 233 F (45) - 47-96 65.8 ±12.2
286 M (55) - 46-93 62.7 ±10.4
PD – Mayo Clinic
DNA from patients with PD originating from various sites within the United
States and from different European countries has been collected by a number
of investigators, and is available at the Mayo Clinic Jacksonville. Some of these
samples were used in addition to samples from Trondheim in Paper I.
Dementia – Trondheim
For Paper III we used a series of 242 patients recruited from the geriatric and
neurological outpatient clinics at St. Olav's Hospital in Trondheim and from local
nursing homes. Medical history, clinical and neurological examination were
completed by a neurologist (Sigrid Botne Sando) for all patients. Examination
included the use of Mini-Mental State Examination (MMSE), Clock Drawing Test
(113), Montgomery and Åsberg Depression Rating Scale (MADRS) (114) and
the motor examination part of the Unified Parkinson’s Disease Rating Scale
(UPDRS III). Available relatives were interviewed about the medical, social and
family history, the disease course and completed Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE) (115). Medical records, laboratory
blood tests and brain images (CT or MRI) were reviewed.
Guidelines given in the International Classification of Diseases (ICD-10) were
applied for diagnosing dementia. Patients diagnosed with AD fulfilled NINCDS-
ADRDA criteria for possible or probable AD (15). A diagnosis of probable and
possible DLB was made according to the consensus guidelines (116). The
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DSM-IV criteria were used for vascular dementia (VaD), and frontotemporal
dementia (FTD) was diagnosed according to the Lund-Manchester criteria
(117).
The distribution of diagnoses, MMSE scores and demographic data is shown in
Table 6. 103 of the patients (43%) were living in nursing homes, and these
individuals were examined there. A positive family history of dementia in at least
one first-degree relative was noted in 134 (55 %) of the patients. Description of
brain imaging (cerebral MRI or CT) was available in 221 (92%) of the patients.
Table 6. Demographic information on patients included in Paper III.
Clinical
diagnosis
Number
of
samples
Gender (%) Disease onset
(years ± SD)
MMSE
(mean ± SD)
Years of
education
(mean ± SD)
AD 161 F 108 (67)
M 53 (33)
74.2 ± 8.5
72.9 ± 8.4
14.1 ± 7.8
16.0 ± 7.5
8.7 ±  2.2
9.4 ±  2.6
DLB 30 F 13  (43)
M 17 (57)
71.2 ± 8.6
71.2 ± 9.1
20.4 ± 5.6
17.8 ± 8.5
10.2 ± 2.9
10.0 ± 3.0
FTD 8 F 5  (63)
M 3 (37)
66.4 ± 13.6
62.7 ± 12.9
19.8 ± 9.6
20.0 ± 3.5
12.6 ± 1.9
 9.7 ± 1.5
VaD 43 F 27 (63)
M 16 (37)
76.1 ± 5.8
71.4 ± 10.5
18.8 ± 5.7
17.8 ± 7.6
 8.7 ± 2.4
10.7 ± 3.0
Total
number
242 F 153 (63)
M 89 (37)
74 ± 8.5
72 ± 9.1
15.7 ± 7.7
16.8 ± 7.6
 8.9 ±  2.4
 9.7 ± 2.7
AD – Alzheimer’s disease, DLB – Dementia with Lewy bodies, FTD – Frontotemporal dementia,
VaD – Vascular dementia. Three of the patients diagnosed with FTD also had motor neuron disease
(FTD-MND), which was confirmed by neurophysiological examinations
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3.2 Brain tissue
In Paper IV, we used tissue from several brain banks available at the
Department of Neuroscience, Mayo Clinic Jacksonville. Cases with clinical or
pathological features consistent with parkinsonism came from the Mayo Clinic
Jacksonville brain bank and the University of Miami/National Parkinson
Foundation Brain Endowment Bank. The screened samples had received a
pathological diagnosis of PD or LBD (n=405), PSP (n=326), and MSA (n=43).
Control groups for this study consisted of brains of clinically normal, aged
individuals (n=156) and subjects with dementia, most of whom had been
referred to the State of Florida Alzheimer’s Disease Initiative Brain Bank (AD;
n=654).
The study presented in Paper IV was based on archival brains, and therefore
details on family history of neurological disease were incomplete and not
routinely recorded in the database. Available medical records were reviewed for
family history and additional information was obtained from the referring
physician. However, the available information was not collected in a
standardized manner.
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4. Methods
4.1 Molecular biology
Genomic DNA from study individuals and brains were extracted from whole
blood and brain tissue using different standard methods. Polymerase chain
reaction (PCR) amplifications were performed on thermal cyclers using the
specific primers and conditions as described in Paper I-V. After PCR the LRRK2
and PINK1 genes were sequenced using the same primers as for the PCR and
the BigDye Terminator v. 3.1 cycle sequencing kit (Applied Biosystems).
Subsequent capillary electrophoresis was carried out on an ABI 3100
automated capillary machine (Applied Biosystems). Heterozygote base calls
and sequence alignment were performed with Sequencher (Gene Codes
Corp.).
In addition to direct sequencing, mutation screening was performed using
several different methods. Some missense mutations result in the loss of a
recognition sequence for a particular restriction enzyme. This enzyme can be
used to genotype the sample without completely sequencing it, by analyzing
restriction fragment length polymorphisms on an agarose gel after PCR and
subsequent digestion with the enzyme. The Lrrk2 R1441C/H/G substitutions
were genotyped using the BstUI enzyme (Figure 5).
DNA was genotyped for several of the other mutations using allelic
discrimination assays, employing TaqMan chemistry on an ABI 7900 (Applied
Biosystems). Analyses were performed using Sequence Detection System 2.2
software (Applied Biosystems).
Figure 5. An agarose gel image of the
BstUI digestion for the identification of the
mutant allele. Lane M contains a 1Kb DNA
size ladder. Lanes 1, 3, & 5 are DNA
samples and lanes 2, 4 & 6 are positive
controls for the heterozygous
R1441C/H/G, respectively.
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In the study presented in Paper I we genotyped 17 microsatellite markers for
linkage and haplotype analyses. Seven published microsatellite markers were
chosen to span the PARK8 region (D12S87, D12S1648, D12S2080, D12S2194,
D12S1048, D12S1301 and D12S1701). LRRK2 is located between D12S2194
and D12S1048. In addition to these seven, we developed ten novel
microsatellite markers in this region by searching for repeat polymorphisms
using RepeatMasker of in silico BAC sequence (UCSC Human Genome
Browser Web site).
For the genotyping of microsatellite markers one primer of each pair was
labeled with a fluorescent tag.  PCR reactions were carried out under standard
conditions and PCR products were run on an ABI 3100 genetic analyzer.
Results were analyzed using Genescan 3.7 and Genotyper 3.7 software
(Applied Biosystems). Marker allele frequencies were not publicly available for
the novel markers and they were therefore estimated by genotyping 93
unrelated North American individuals.
In Paper V we designed an assay to detect multiplications and deletions of the
PINK1 gene. Absolute quantitative PCRs of PINK1 were performed using the iQ
SYBR Green Supermix kit (Biorad). Absolute quantification of DNA template
was calculated from a standard curve using the MJ Opticom Monitor v.3.1.  For
this assay the concentrations of PINK1 exon 4 and 7 were individually analysed
and compared with concentrations of the external control gene, human serum
albumin. Each sample was run in a triplicate reaction.
Relative gene dosage ratios with standard deviations were calculated by
dividing the normalised mean PINK1 quantity by the mean albumin quantity.
The advantage of this assay was that we could design positive controls for
deletion and multiplication mutations by using other amounts of DNA (Figure 6).
A relative ratio with standard deviations between 0.75 and 1.25 was considered
normal, a heterozygous deletion was expected at a ratio between 0.25 and
0.75, and a duplication was expected between 1.25 and 1.75. Ambiguous
samples were re-run in triplicate with DNA from a separate tube.
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4.2 Pathology
In Paper IV neuropathological review of available autopsy material from
subjects carrying the G2019S mutation performed. Postmortem examination of
the brain followed standard protocols to identify macroscopic and microscopic
evidence of disease. Sections from tissue blocks were stained with hematoxylin
and eosin, thioflavin-S and anti-a-synuclein antibodies. A pathological diagnosis
of LBD had been made based on the presence of classic intracytoplasmic Lewy
bodies within neurons of pigmented brain stem nuclei and/or similar inclusions
in limbic and neocortical regions.
For quantitative assessment areas chosen to represent brain stem, paralimbic
areas and neocortex were studied. Cortical Lewy bodies were quantified using
a-synuclein immunohistochemistry in four cortical regions at magnification x200.
In each case Lewy body distribution and frequency was evaluated using the
consortium guidelines Lewy body scores, and the case were classified into
brainstem dominant, transitional and diffuse categories (116).
Alzheimer’s disease pathology was assessed by the use of thioflavin-S
fluorescence microscopy in four cortical regions. Average density of senile
plaques at magnification x100 and of neurofibrillary tangles (NFT) at
Normalized ratio albumin/PINK1 exon7
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Figure 6. Relative ratios of gene dosage of PINK1 compared to albumin for 17 EOP
patients (dark grey); the bars represent standard deviations. The ratios for two deletion
controls and two triplication controls are shown in light grey.
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magnification x400 was calculated. Braak NFT staging was performed (118).
The NFT stages range from 0 to VI, with IV and greater characteristic of AD.
4.3 Statistics
Linkage
Linkage is the tendency for genetic markers to be inherited together in case of
recombination of the genetic material because of their location near one another
on the same chromosome. It is possible to calculate the overall likelihood of a
pedigree, on the alternative assumptions that the loci are linked (recombination
fraction = ?) or not linked (recombination fraction = 0.5). The ratio of these two
likelihoods gives the odds of linkage, and the logarithm of the odds is the LOD
score. Morton demonstrated that LOD scores represent the most efficient
statistic for evaluating pedigrees for linkage (119). In a set of families, the
overall probability of linkage is the product of probabilities in each individual
family, therefore LOD scores can be added up across families.
Linkage analysis can be more efficient if data for more than two loci are
analyzed simultaneously, as this overcomes problems caused by limited
informativity of markers. In Paper I, we calculated multipoint LOD scores for all
families under the assumption of an autosomal dominant model by using the
program GENEHUNTER-PLUS (120). The frequency of the deleterious allele
was set at 0.0001; marker allele frequencies were determined empirically. The
map positions for each marker were taken from Rutgers combined linkage-
physical map version 1.0 (MAP-O-MAT web site). For tightly linked loci with no
observed recombinants, inter-marker genetic distances were assigned as
0.01cM.
Association
Genetic association is the occurrence together in a population, more often than
can be readily explained by chance, of two or more traits of which at least one is
known to be genetic. Association between genetic polymorphisms and disease
was in Paper V calculated by using Pearson’s chi-square test.
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Penetrance
Age-dependent penetrance was in Paper I estimated as the probability of a
gene mutation carrier becoming affected, at a given age, within the families.
The number of affected mutation carriers within 5-year age groups was divided
by the total number of carriers (both affected and unaffected) within that group.
Haplotype analysis
A haplotype is a particular combination of alleles that are closely linked on a
chromosome. In Paper I, haplotypes were established manually for families with
known phase, after genotyping 21 polymorphic genetic markers (17
microsatellites and 4 SNPs). Haplotype frequencies in the general population
were estimated from genotypes of 93 unrelated individuals by use of an
estimation-maximization algorithm (121).
4.4 Ethics
All patients and controls included in the studies have provided informed
consent. Study protocols for both the sample series from Trondheim
(Parkinson’s disease and dementia) have been approved by the Regional
Committee for Medical Research Ethics in Central Norway. Studies performed
at the Mayo Clinic Jacksonville have been approved by the Mayo Clinic
Institutional Review Board. The biobanks in Trondheim have the necessary
approval required by Norwegian biobank law.
Results of genetic examinations as a part of the studies have not been given to
patients and family members participating in the study. The identity of study
participants has remained unknown for researchers working on the projects,
except for those who have been involved in clinical examinations of patients.
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5. Results
5.1 Review of paper I
Identification of a novel LRRK2 mutation linked to autosomal dominant
parkinsonism: Evidence for a common founder across European
populations.
Jennifer Kachergus*, Ignacio F. Mata*, Mary Hulihan, Julie P. Taylor, Sarah
Lincoln, Jan Aasly, J. Mark Gibson, Owen A. Ross, Timothy Lynch, Joseph
Wiley, Haydeh Payami, John Nutt, Demetrius M. Maraganore, Krzysztof
Czyzewski, Maria Styczynska, Zbigniew K. Wszolek, Matthew J. Farrer, and
Mathias Toft *Both authors contributed equally
Background: Autosomal dominant parkinsonism has been attributed to
pathogenic amino acid substitutions in Leucine-rich repeat kinase 2 (Lrrk2).
Methods and results: By sequencing multiplex families consistent with a PARK8
assignment, we identified a novel heterozygous LRRK2 mutation. A referral
sample of 248 affected probands from families with autosomal dominant
parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a
heterozygous LRRK2 c.6055G>A transition (G2019S). These seven patients
originate from the United States, Norway, Ireland, and Poland. In samples of
patients with idiopathic Parkinson disease (PD) from the same populations,
further screening identified six more patients with Lrrk2 G2019S; no mutations
were found in matched control individuals. Subsequently, 42 family members of
the 13 probands were examined; 22 have an Lrrk2 G2019S substitution, 7 with
a diagnosis of PD. All patients share an ancestral haplotype indicative of a
common founder. Within families, Lrrk2 G2019S segregates with disease
(multipoint LOD score 2.41). Penetrance is age dependent, increasing from
17% at age 50 years to 85% at age 70 years.
Conclusion: Our study demonstrates that Lrrk2 G2019S accounts for
parkinsonism in several families within Europe and North America. Our work
highlights the fact that a proportion of clinically typical, late-onset PD cases
have a genetic basis.
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5.2 Review of paper II
Clinical features of LRRK2-associated Parkinson’s disease in Central
Norway
Jan O. Aasly, Mathias Toft, Ignacio F. Mata, Jennifer Kachergus, Mary Hulihan,
Linda R. White, and Matthew Farrer.
Background: Several pathogenic mutations in the leucine-rich repeat kinase 2
(LRRK2; PARK8) gene have recently been identified in familial and sporadic
parkinsonism. Our objective was to present a detailed clinical study of
Norwegian patients with LRRK-associated disease.
Methods: We screened 435 Norwegian patients diagnosed with Parkinson’s
disease and 519 control subjects for the presence of 7 LRRK2 mutations
previously published. Patients were clinically examined and followed
longitudinally.
Results: Nine patients from seven families were found to be heterozygote
carriers of the LRRK2 c.6055G>A (G2019S) mutation. Twelve of 28 first-degree
relatives also carried the mutation, but only 1 had Parkinson’s disease. The
clinical features included asymmetric resting tremor, bradykinesia, and rigidity
with a good response to levodopa and could not be distinguished from
idiopathic Parkinson’s disease. No patient carried any of the other LRRK2
mutations.
Conclusions: Patients with a Lrrk2 G2019S substitution present with a
levodopa–responsive parkinsonian syndrome with asymmetric resting tremor,
bradykinesia, and rigidity, which are typical of idiopathic PD. The nonmotor
autonomic, psychiatric, and cognitive symptoms are mild. Currently, Lrrk2
G2019S–associated parkinsonism is the most prevalent cause of genetically
determined PD in Norway.
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5.3 Review of paper III
LRRK2 mutations are not common in Alzheimer’s disease
Mathias Toft, Sigrid Botne Sando, Stacey Melquist, Owen A. Ross, Linda R.
White, Jan O. Aasly, Matthew J. Farrer
Background: The development of common age-related neurodegenerative
disorders as Parkinson’s disease and Alzheimer’s disease (AD) is influenced by
genetic factors. Recently, pathogenic mutations in the leucine-rich repeat kinase
2 (LRRK2) gene have been identified in familial parkinsonism. Individuals in
some of these families developed symptoms of dementia with Lewy-bodies and
AD. The LRRK2 gene is also located within a locus on chromosome 12 reported
in late-onset AD, and is therefore a good candidate gene for dementia.
Methods: A series of 242 patients from Norway diagnosed clinically with
dementia were included in the study, the majority being diagnosed with AD
(n=161). 43 patients with vascular dementia, 30 patients with dementia with
Lewy bodies and 8 with frontotemporal dementia were also included. Individuals
were screened for the presence of seven known pathogenic mutations
previously reported in the LRRK2 gene.
Results: We did not identify LRRK2 mutations in our series of dementia
patients.
Conclusion: Our results indicate that known pathogenic mutations are not
common in patients clinically diagnosed with AD. However, these results do not
exclude a possible role of other genetic variants within the LRRK2 gene in AD
or other forms of dementia.
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5.4 Review of paper IV
Lrrk2 and Lewy Body Disease
Owen A. Ross, Mathias Toft, Andrew J. Whittle, Joseph L. Johnson, Spiridon
Papapetropoulos, Deborah C. Mash, Irene Litvan, Mark F. Gordon, Zbigniew K.
Wszolek, Matthew J. Farrer, and Dennis W. Dickson
Background: The Lrrk2 kinase domain G2019S substitution is the most common
genetic basis of parkinsonism. Patients harboring the G2019S substitution
usually present with clinical PD, but pathology has yet to be clearly defined. The
rationale for our study was to provide a consensus on the pathology associated
with Lrrk2 G2019S–associated disease.
Methods: We screened the Mayo Clinic Jacksonville brain bank and University
of Miami/National Parkinson Foundation Brain Endowment Bank for cases with
clinical or pathological features consistent with parkinsonism. The screened
samples included PD or LBD (n=405), PSP (n=326), and MSA (n=43). Control
groups consisted of brains of clinically normal, aged individuals (n=156) and
subjects with AD (n=654). DNA was obtained from frozen brain tissue and
genotyped for the exon 41 LRRK2 6055G>A (G2019S) mutation. Available
medical records from mutation carriers were reviewed and neuropathological
examination was performed.
Results: Lrrk2 G2019S was observed in approximately 2% (n = 8) of our
PD/LBD cases (n = 405). The mutation was also found in one control and one
Alzheimer’s disease patient, reflecting reduced penetrance. Neuropathological
examination showed typical Lewy body disease, with brainstem-type LBD (n=4),
transitional LBD (n=3), and diffuse LBD (n=1).
Conclusion: The most common neuropathology of G2019S-associated PD is
Lewy body disease. Therapeutic strategies targeted at modulating Lrrk2 kinase
activity may be important to treat patients with genetically defined familial or
typical sporadic PD.
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5.5 Review of paper V
PINK1 mutation heterozygosity and the risk for Parkinson’s disease
Mathias Toft, Ronny Myhre,  Liza Pielsticker,  Linda R. White,  Jan O. Aasly, and
Matthew J. Farrer
Background: Mutations in the PINK1 gene have been identified in recessively
inherited and seemingly sporadic early-onset parkinsonism (EOP).
Objective: Our objective was to further evaluate the pathogenic role of PINK1
mutations in familial and sporadic PD.
Methods: We included a total of 131 patients diagnosed with PD from an
ongoing study of the genetics of PD in Norway. Eighty-nine subjects had EOP
(onset =50 years); the remaining had familial late-onset disease (mean age at
onset 64 years). PINK1 analysis included complete sequencing and an
assessment of gene dose alterations. Mutations identified were examined in
350 ethnically matched control individuals.
Results: Heterozygous missense mutations in PINK1 were found in three of 131
patients; none of the patients carried homozygous or compound heterozygous
mutations. One of these three patients had a father affected by PD, and he
carried the mutation. In addition, three novel and seven known polymorphic
variants were identified in the gene, although none appeared associated with
disease risk. A parkinsonian phenotype, with asymmetric onset and without any
atypical features, characterised the clinical presentation of the three patients
with heterozygous mutations.
Conclusions: Mutations in the PINK1 gene are rare in Norwegian early-onset
and familial PD patients. However, our data suggest that some heterozygous
mutations might increase the risk of developing PD.
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6. Discussion
6.1  Identification and evidence for pathogenicity of Lrrk2
G2019S
In Paper I we identified a novel c.6055G>A mutation in the LRRK2 gene. This
mutation was found by sequencing of genomic DNA from probands of six small
families with positive LOD scores for markers within the PARK8 locus from a
previous study (108). Affected members of one of the six families, Family 3211
originating from Ireland, carried this mutation. No LRRK2 mutation was found in
the remaining five families.
We screened for this specific mutation in an additional 242 affected probands of
familial parkinsonism consistent with autosomal dominant parkinsonism. In
addition, we examined a total of 806 patients with sporadic PD from Norway,
Ireland and Poland, and 2260 controls. The results of this screening and
subsequent analyses provided strong evidence for pathogenicity of the
identified mutation.
Genetic evidence
The c.6055G>A mutation causes an amino acid alteration in the predicted Lrrk2
protein, replacing a glycine residue with a serine at position 2019 (p.Gly2019Ser
= G2019S). This amino acid is located within a region evolutionary highly
conserved across species (Figure 7). In addition, a previously described I2020T
mutation affects an adjacent codon, further highlighting the functional
importance of the region.
However, not only is this residue conserved across species, but also between
different human kinases. The substitution is localized within the functionally
important kinase domain of the Lrrk2 protein, which belongs to the MAPKKK
subfamily of kinases. The active site of kinases is located in a cleft between an
N-terminal and a C-terminal lobe and is covered by an activation segment in its
inactive form. The activation segment is a region of the kinase domain that
undergoes crucial structural changes necessary to allow access to peptide
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substrates and also to orientate key catalytic amino acids within the cleft of the
kinase (122). In different kinases, the activation segment starts and ends with
the conserved residues DF/YG and APE, respectively (123). The Lrrk2 G2019S
substitution changes the highly conserved glycine (G) at the start of this
segment (Figure 8).
In other kinases, oncogenic mutations in residues within the activation segment
of the kinase domain have an activating effect (124). We therefore postulated in
Paper I, and in an additional letter in the Lancet, that mutations in this region
might have an activating effect on the kinase activity of Lrrk2 (125). A mutation
causing “gain of function” of the resulting protein would also be compatible with
the dominant mode of disease transmission observed in the families. The two
pathogenic mutations identified in this region introduce serine (G2019S) and
threonine (I2020T) residues, which may be potential targets for phosphorylation,
increasing activity or altering substrate specificity.
Figure 7. Lrrk2 with the novel G2019S substitution
a) Schematic drawing of Lrrk2 with predicted protein domains
b) The human Lrrk2 protein sequence in the region of the G2019S mutation aligned
with orthologs from rat, mouse, frog and puffer fish.
c) Chromatogram showing the c.6055G>A mutation (G2019S).
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Statistical evidence
In Paper I the Lrrk2 G2019S mutation co-segregated with disease within all
families where the mutation was found in more than one affected individual.
However, one affected member of one family did not carry the disease-
associated PARK8 haplotype. He had akinetic rigid parkinsonism unresponsive
to levodopa, and he was thus considered a phenocopy and excluded from
further analyses.
Evidence for linkage to the PARK8 locus was found across families, with a
combined maximum multipoint LOD score of 2.41, corresponding to a P value
of 4.3x10-4. Positive LOD scores were found in all families. As only a defined
chromosomal region was investigated, rather than a genome-wide search, the
mLOD score exceeds that required for significance, P=0.01 (126).
In total, we found the G2019S mutation in seven of 248 families with autosomal
dominant parkinsonism (2.8%) and six of 806 patients with seemingly sporadic
PD (0.7%). We did not identify the mutation in any of 2260 control individuals,
demonstrating a clear association between the variant and disease. At the
same time as Paper I was published, three other groups reported the finding of
G2019S in a number of patients from several populations. This established that
the mutation is relatively frequent in PD and rare in controls (127-129).
Numerous studies from a range of different populations have now confirmed
these findings.
Figure 8. Aligned amino acid sequences of the activation segment of human kinases.
53
Evidence from functional studies
Several studies have indicated that the G2019S mutation increase the kinase
activity of the protein, as proposed in Paper I. West and colleagues found that
the Lrrk protein is mainly localized in cytosplasm, but also associates with the
mitochondrial outer membrane. In an in vitro kinase assay, the G2019S
mutation caused an increase in autophosphorylation and phosphorylation of
myelin basic protein (130). Mutant Lrrk2 causes degeneration in different cell
lines, including neuronal cells (131). This cell death is dependent on the kinase
activity, which is regulated by GTP via the Lrrk2 Roc domain (132, 133). The
substrates of Lrrk2 and mechanisms of neuronal cell death are still unknown.
6.2 Frequency of LRRK2 mutations
In Paper I we identified the G2019S mutation in seven of 248 families with
autosomal dominant parkinsonism (2.8%) and six of 806 patients with
seemingly sporadic PD (0.7%). Screening of 6 other mutations in the Norwegian
patients included in Paper I did not reveal any other LRRK2 mutations in our
population (Paper II). In Paper IV we found G2019S in 8/405 pathological cases
with LBD (2%). Our conclusion is that, at least in Norway, G2019S is the most
frequent pathogenic Lrrk2 amino acid substitution and the most common known
genetic cause of PD. On the other hand, other LRRK2 mutations are relatively
rare in Norway.
The frequency of G2019S varies between different studies. In studies of this
mutation in familial or autosomal dominant PD, the frequency has varied
between 0% and 37% (134, 135). Each study used different criteria for
autosomal dominant or familial parkinsonism, which probably explains some of
the different mutation frequencies identified. In Paper I, we used a relatively
liberal criterion for inheritance compatible with autosomal dominant disease,
whereby at least two affected individuals in two consecutive generations were
required for inclusion into the study.
The frequency of G2019S also seems to be population specific. The highest
mutation frequencies have been found among North African Arabs (41%) and
Ashkenazi Jews (18%), also suggesting the likely region of origin of the
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mutation (135, 136). It is likely that the mutation has been spread by migration
of Arab and Jewish populations, indicated by a South to North gradient of
mutation frequency. The mutation frequency is high in Spain and Portugal,
where G2019S has been found in between 3% and 8% of studied patients (137-
139). In Northern European and North American populations, which mainly is of
Northern European origin, most studies have found a mutation frequency of
G2019S between 0.5% and 1.5% (128, 140-142), comparable to our results
from the Norwegian, Irish and Polish populations. In Asian populations G2019S
seems to be very rare (143-145).
The frequencies reported might be overestimates of the true prevalence in the
different populations. Most studies have been performed in clinic based series,
mainly from movement disorders specialists, including the series we used in
Papers I and II. This might bias the results, as patients with familial disease
could be more aware of the disease and seek specialized hospital care (referral
bias). The mutation prevalence in a community-based PD cohort from the UK
was 0.4% (146), and a similar study from the US showed a prevalence of 0.5%.
Both these studies found lower mutation frequencies than studies from the
same countries using clinic-based study designs.
Several other mutations than G2019S have been identified in the LRRK2 gene,
both in families with autosomal dominant parkinsonism and in individuals with
seemingly sporadic disease. Segregation analyses within families provides
statistical evidence for the pathogenicity of some of the published mutations
(R1441C, R1441G, Y1699C, G2019S and I2020T).
A number of additional mutations have been published (Table 7). However,
these variants have been identified only in small families or single individuals. In
a paper not included in this thesis we have examined the role of one of these
variants in PD (R1514Q), and demonstrated that this variant is not associated
with disease and does not segregate within a large family (147). Similar studies
are needed for each variant to determine its pathogenicity. They should
therefore be considered putative pathogenic variants until more data is available
and are not discussed further in this thesis.
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Table 7. Putatively pathogenic LRRK2 mutations
Exon Amino Acid Change Protein Domain Reference
19 R793M Berg et al 2005
21 Q930R Berg et al 2005
23 R1067Q LRR Skipper et al 2005
24 S1096C LRR Berg et al 2005
24 L1114L LRR Zimprich et al 2004
25 I1122V LRR Zimprich et al 2004
25 A1151T LRR Schlitter et al 2006
27 S1228T LRR Berg et al 2005
29 I1371V Roc Paisan-Ruiz et al 2005
31 R1441H Roc Mata et al 2005
IVS31+3 A>G Roc Zabetian et al 2005
32 R1514Q COR Mata et al 2005
IVS33+6 T>A COR Skipper et al 2006
38 M1869T COR Mata et al 2005
38 G1874X COR DiFonzo et al 2005
39 R1941H MAPKKK Khan et al 2005
41 I2012T MAPKKK Tomiyama et al 2006
47 T2356I WD40 Khan et al 2005
48 G2385R WD40 Mata et al 2005
To date, few studies have reported the frequency of LRRK2 mutations other
than G2019S. The R1441G mutation was common (8%) in a series of patients
from the Basque population (Paisan-Ruiz et al. 2004), and this mutation has
also been found in patients from other regions of Spain (Mata et al. 2005b).
R1441G seems far less frequent in other populations. The R1441C mutation
has been identified in patients from different populations, indicating that this
mutation might be the second most common outside Spain (111, 148, 149).
6.3 Penetrance and haplotype analyses
Penetrance estimations
As with PD in general, age is a risk factor for LRRK2-associated parkinsonism.
The age of onset is variable, ranging from the fourth to the ninth decade, with
the average age of onset between 55 and 65 years in the various families and
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studies (109, 111, 129). Penetrance of LRRK2 mutations depends on age and
estimates vary among mutations and populations.
In Paper I we calculated penetrance of the G2019S mutation and found that it
increases in a close to linear fashion from 17% at age 50 years to 85% by age
70 years (Figure 9). Age at onset was variable, both within and between
different families, with a mean age at onset of 56.8 years. Most mutation
carriers had late-onset disease (>50 years of age). The variable age at onset
suggests that other susceptibility factors, environmental or genetic, might
influence the phenotype. Since the penetrance of LRRK2 mutations depends on
age, mutations are also found in patients with a negative family history for PD
and seemingly sporadic disease. This has important implications for genetic
screening and counseling of PD patients.
Lifetime penetrance of the G2019S mutation has also been calculated for the
Ashkenazi Jewish population. A penetrance of around 35% was found using
different methods than we used in Paper I (136). Our results could be an
overestimate, since some of the patients in our study were from selected
families. Penetrance in families with a clear autosomal inheritance is likely to be
higher than in the general population. Despite this, a penetrance of 35% seems
low, taking into account the low frequency of G2019S found in control
Figure 9. Probability of becoming affected by parkinsonism, in Lrrk2
G2019S carriers, as a function of age.
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individuals. Ideally, penetrance should be calculated from population-based
studies, but data from such studies have so far not been published.
Few penetrance estimates have been published for other mutations than
G2019S. In the Sagamihara kindred, segregation analysis of the disease-
associated haplotype indicated penetrance of about 65% (106). The oldest age
at onset in families with the R1441G substitution was 80 years (110), indicating
a high penetrance in this age group.
Haplotype analyses
All mutation carriers in Paper I, although a family history was not always
apparent, shared a small ancestral haplotype of a size of 145 to 154 kb. This
indicated that the mutation arose in an ancient common founder. It also
suggested that this specific mutation is frequent and spread throughout variuos
populations, as now demonstrated by the identification of G2019S in a high
number of populations.
Other studies have also demonstrated that most European and North American
G2019S carriers share a haplotype (150, 151). Lesage and colleagues found
that the region shared was only 60 kb (151). However, it has been shown that
one of the markers (D12S2515) used in both this and our study is unstable.
Thus, allelic differences observed among haplotypes at this marker could be
due to recurrent mutations rather than recombination, affecting the calculated
size of the shared chromosomal region (145). Separate founding events for
G2019S have recently been suggested for a proportion of North American and
Japanese patients with this mutation (145, 152).
6.4  Clinical features of LRRK2-associated parkinsonism
In Paper II we studied in detail the clinical presentation of G2019S-associated
PD in 10 Norwegian patients. Our main conclusion was that motor symptoms,
cognitive performance and response to dopaminergic treatment were
indistinguishable from those observed in patients with sporadic late-onset PD.
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In our study, resting tremor was the presenting symptom in six of ten patients.
All except one patient subsequently developed resting tremor during the course
of their disease. Bradykinesia was a consistent finding in all patients and was
the first symptom observed in three of them. The poverty of movement was
generally moderate and episodes of severe akinesia were only observed in off-
periods in two patients.
Nine of the 10 patients had a good to excellent response to levodopa or other
dopaminergic agents. In one patient the response was less profound.
Levodopa-induced dyskinesias were observed in six patients. The dyskinesias
were most pronounced in the two early-onset cases. Good response to
dopaminergic treatment and frequent development of dyskinesias are also
found by other investigators (129, 150). One study found less severe clinical
symptoms in G2019S carriers, despite an increased disease duration,
compared with other patients with familial parkinsonism (129).
We found no indication of early dementia, autonomic dysfunction, or other
atypical neurologic signs being more frequent than in other patients with PD,
which is in accordance with other studies (127, 150). Of interest, levodopa-
responsive foot dystonia has been the initial symptom in several patients,
including one patient in Paper I (128, 150). Further studies are needed to
assess the frequency of dystonia, but dystonia might be more frequent in
LRRK2-associated parkinsonism.
The results in Paper II are similar to the findings in patients with other
pathogenic LRRK2 mutations (Table 8). In the Sagamihara kindred (I2020T),
affected members had asymmetric parkinsonism with a favorable response to
dopaminergic treatment, and none of the individuals presented with any atypical
symptoms (106, 107). Symptoms typical of sporadic PD responding to levodopa
treatment were also found in the German family with the I2020T mutation (111).
Slowly progressive parkinsonism with tremor as the presenting and initially
predominant symptom was reported in R1441G-associated disease (109).
These patients had a good response to dopaminergic treatment and developed
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motor complications typical of PD after 6 to 8 years of treatment. No cognitive
decline was observed even after long disease duration, but delusional and
paranoid hallucinations occurred in one affected individual. Writer’s cramp and
foot dystonia were present in a member of one family (109). In a second report,
the clinical features were consistent with sporadic late-onset PD (153).
Resting tremor was not as prominent in Family D (Western Nebraska), a large
family with an R1441C substitution affecting the same codon as the variant
found in the Basque and Spanish families. The most common initial
presentation was bradykinesia (60%) and unilateral resting hand tremor (40%).
Response to levodopa therapy was excellent, and motor complications have
developed in half the patients receiving treatment. The phenotype of this family
is indistinguishable from typical late-onset PD, except in one family member
who also developed supranuclear gaze palsy but remained responsive to
levodopa until death (154, 155).
Other atypical symptoms have been observed in a second family, Family A
(German-Canadian), carrying the Y1699C substitution. This family is
characterized by a parkinsonian syndrome responsive to dopaminergic
treatment, with subsequent development of motor complications. However, one
family member had clinical amyotrophy characterized by muscle weakness,
atrophy, and fasciculations. Two other mutation carriers in this family presented
with dementia (111, 156).
The number of patients studied so far is limited, especially for other mutations
than G20192S. Further studies are needed to determine if the atypical
symptoms found in some families with LRRK2 mutations are typical for LRRK2-
associated PD. The main findings from clinical studies support our results in
Paper II. The clinical presentation of the disease is heterogeneous, but the vast
majority of patients have clinical symptoms within the spectrum normally found
in idiopathic PD, and they fulfill diagnostic criteria for the disease.
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6.5 Neuropathology of LRRK2-associated parkinsonism
In Paper IV we screened DNA from a large number of cases (total n=1584) to
establish the neuropathology associated with the Lrrk2 G2019S mutation. The
DNA was obtained from several brain banks and included cases with
neuropathologies typical of different synucleinopathies and tauopathies, as well
as normally aged individuals. We identified a total of 10 cases with the mutation;
eight with Lewy body disease (LBD), one with Alzheimer pathology (discussed
below) and one normally aged brain without any significant neuropathology.
The main conclusion of Paper IV is that the most common neuropathology of
G2019S-associated Parkinson’s disease is Lewy body disease. In all respects,
the LBD was typical in these cases, with prominent involvement in the
brainstem monoaminergic nuclei, basal forebrain, and limbic cortex.
Neuropathologic examination revealed brainstem-type LBD in 4 caes,
transitional LBD in 3, and diffuse LBD in 1 case. Only three of the cases had a
known family history of PD, confirming the occurrence of this mutation in both
familial and sporadic PD.
Four of the cases had autonomic dysfunction. In one case material was
available to demonstrate a correlation between these symptoms and the
presence of Lewy bodies and Lewy neurites in the autonomic nervous system,
including the intermediolateral column of the spinal cord and the myenteric
plexus in the large intestine. This demonstrates that, at least in advanced
stages, the a-synuclein associated pathology extends beyond the central
nervous system.
Braak and colleagues have proposed a neuropathological staging protocol for
PD, where the disease process begins in the dorsal nucleus of the vagal nerve.
From there, the pathology spreads in an upward path through the lower
brainstem and basal forebrain until it reaches the cerebral cortex (9). In our
study, we found no apparent relationship between age at disease onset,
disease duration, and the stage of LBD observed. The mutation carrier with the
longest duration of disease (31 years) had only brainstem LBD. In a study of the
association of cognitive status with neuropathologic stages of PD, cognitive
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performance measured by the MMSE test did not correlate significantly with
disease duration, age at disease onset, or age at death (10). This indicates that,
although the pathology might spread in the proposed pattern, the rate of
progression of both neuropathological findings and cognitive decline is very
different between affected individuals.
Two of the LBD cases in Paper IV presented clinically with dementia. Both had
transitional LBD and one of them had sufficient neurofibrillary pathology to
warrant a diagnosis of AD. Dementia was not noted in the patient with diffuse
LBD, but the clinical information available was incomplete. The main substrate
of dementia in PD is LBD (157). Cognitive status of patients and the stage of
pathology correlates, indicating that the risk of developing dementia in PD
becomes greater as the disease process in the brain progresses (10). However,
as also demonstrated in our patients, cognitive decline can develop in the
presence of mild PD-related cortical pathology and, conversely, widespread
cortical lesions do not necessarily lead to cognitive decline (10, 158). If Lewy
bodies do not accurately predict cognitive decline in PD, this raises the question
whether Lewy bodies are markers for dying neurons, or if they represent a
protective mechanism of surviving cells. Recent studies of other
neurodegenerative disorders with inclusion bodies have supported the latter
theory. For instance, inclusion body formation reduced the risk of neuronal
death in a study of a model of Huntington’s disease (159).
The healthy control subject in our study who carried Lrrk2 G2019S died at 68
years of age after an acute myocardial infarction. No significant
neurodegenerative pathology was observed. This subject had no documented
family history of PD. These findings are consistent with the reduced penetrance
of Lrrk2 G2019S already discussed.
Two other reports of autopsy findings for the Lrrk2 G2019S mutation have been
published, and support the conclusion that the main pathological substrate is
LBD. Histopathologic examination of three patients in a study by Gilks and co-
workers showed nigral cell loss with typical Lewy bodies. In two of the three
patients, Lewy bodies were present in the limbic cortices, whereas the last case
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showed signs of pathologic aging, with diffuse senile plaques and occasional
neurofibrillary tangles (128). Giasson and colleagues reported pathological
findings in three patients. Two patients demonstrated classical LBD, one patient
also had concurrent AD pathology. The third patient was characterized by
parkinsonism without Lewy bodies but demonstrated dystrophic neurites in the
substantia nigra which stained for Lrrk2 using a Lrrk2 antibody (160).
Neuropathologic findings have also been reported for 3 other LRRK2 mutations.
In contrast to the pathology of idiopathic PD, these examinations have shown
strikingly diverse and pleomorphic findings. Neuronal loss and gliosis in the
substantia nigra are found in all cases. However, various intracellular inclusions
have been demonstrated.
In the Sagamihara kindred (I2020T), brain autopsy has been reported in 4
cases, which were all diagnosed as “pure nigral degeneration”. The
examinations showed mild to moderate nigral degeneration without any Lewy
bodies or other coexisting pathology. No other pathologic changes were
reported in other nuclei of the basal ganglia, in the cerebral cortex, or in the
cerebellum (106, 107).
Four members of Family D (Western Nebraska; R1441C) have come to
autopsy, all presenting with neuronal loss and gliosis of the substantia nigra.
However, variable a-synuclein and tau pathology was demonstrated in the
affected individuals, all carrying the same LRRK2 mutation. Lewy body
pathology was found in two cases; in one case, Lewy bodies were restricted to
brainstem nuclei, whereas the pathology was more widespread in the second
patient. One family member had a tauopathy with neurofibrillary tangles and
neuropil threads, qualitatively similar to the pathologic findings characteristic of
PSP. The fourth family member showed ubiquitin-immunoreactive neuronal
inclusions, without Lewy bodies or tau-related pathology (111, 155).
A number of cytoplasmic and nuclear inclusions were found in two members of
Family A (German-Canadian; Y1699C). The nuclear inclusions were similar to
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Marinesco bodies, although the neuronal cytoplasmic inclusions appear to be
novel and are unclassified. Other patients from Family A had pathologic
evidence of minimal anterior horn cell degeneration, indicating mild motor
neuron disease, and one individual met neuropathologic criteria for AD (111,
156). Interestingly, brainstem LBD was found in a British patient carrying the
same Y1699C mutation (161).
It is currently unknown why the various mutations in the LRRK2 gene are
associated with so different pathologies. One explanation would be that the
Lrrk2 protein functions in a pathway upstream of other proteins implicated in the
pathogenesis of neurodegeneration. Substrates of Lrrk2 GTPase and kinase
activities have to be identified to further understand the molecular mechanisms
and how the different pathologies develop.
6.6 LRRK2-mutations in Alzheimer’s disease and other
neurodegenerative disorders
As discussed above, patients affected by parkinsonism carrying a LRRK2
mutation generally present clinically with symptoms reminiscent of idiopathic
PD. However, some individuals carrying LRRK2 mutations have exhibited
cognitive dysfunction, and co-existing Alzheimer-type pathology has been
identified in several LRRK2 mutation carriers. In addition, tau pathology similar
to that found in PSP, has been demonstrated in a mutation carrier (155). This
indicated that the Lrrk2 protein could be implicated in the aggregation of
misfolded proteins in several neurodegenerative disorders, including AD and
other tauopathies, as studied in Paper III and IV.
In Paper III we studied the presence of seven mutations in the LRRK2 gene in a
series of Norwegian patients with dementia. Of the 242 patients, 161 had
clinical diagnosis of probable or possible AD, and no mutation carriers were
identified. From these results we concluded that LRRK2 mutations are not a
common cause of AD. The study population was limited and only seven
mutations were examined. The possibility of other LRRK2 mutations being
present in our series can therefore not be excluded. Extensive sequencing of
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the large LRRK2 gene would have been required to address this question, but
this was not possible to perform within the available financial resources. The
number of patients with diagnoses other than AD in the study was small. We
can therefore not make definitive statements about a possible role of LRRK2 in
these disorders, and we can only conclude that we did not find any mutations in
our material.
Another limitation of the study was that all diagnoses were clinical, no
neuropathological data were available. Clinical diagnoses of the various
dementias are difficult, but have improved by the use of validated diagnostic
criteria. The NINCDS-ADRDA criteria used for AD in Paper III have been
associated with diagnostic accuracy rates of over 80% (162).
Paper III does not exclude the possibility of other genetic variants within the
LRRK2 gene conferring susceptibility to AD. A locus on chromosome 12
conferring susceptibility to late-onset AD was reported by Pericak-Vance and
colleagues (163). Additional evidence for a locus on this chromosome has been
reported in subsequent linkage studies (16). In a fine-mapping study of this
locus, evidence for linkage was greatest in families where at least one affected
individual had a neuropathologic diagnosis of a different form of dementia,
dementia with Lewy bodies (DLB) (164). One could therefore speculate that the
linked region is a locus for LBD and not AD.
The chromosome 12 locus is large and contains a considerable number of
genes, including LRRK2, which is located underneath the linkage peak in the
study. Studies of the possible association between common genetic variants
within LRRK2 and AD or DLB have so far not been published. However, no
association between common genetic variability within the LRRK2 gene has
been found for PD in most studies, making it less likely that such an association
will exist for AD (165, 166).
In Paper IV, 654 cases with pathologically confirmed AD were screened for the
G2019S-mutation, and one mutation carrier was identified. In addition to
neurofibrillary pathology, this individual showed Lewy bodies in the amygdala,
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but not in brainstem nuclei or cortex. Such amygdala-only Lewy bodies are a
relatively common finding in advanced AD (167). One of 156 clinically normal,
aged individuals screened for the mutations also carried the G2019S variant.
This individual died at the age of 68 and did not have pathology on brain
examination. Our interpretation of the finding of a LRRK2 mutation in a case of
AD and a healthy control was that it might have been a coincidental finding and
a result of the reduced penetrance of G2019S-associated parkinsonism.
Papers III and IV suggest that LRRK2 mutations are not frequent in
neurodegenerative disorders other than familial and apparently sporadic PD.
This finding is now supported by several other studies. Zabetian and colleagues
did not find the G2019S mutation in a series of 754 patients with AD, of which
histopathological data was available for 47% of the subjects (168). In a
screening for the G2019S mutation in patients with PD, AD (n=1444), PSP
(n=186) and other neurodegenerative disorders, the mutation was only found in
patients with PD (169). Studies of patients with dementia and Parkinson plus
syndromes from Asian populations have also failed to identify any mutations
(170, 171). Finally, in a paper not included in this thesis we examined a series
of 244 cases diagnosed as having PSP on the basis of pathologic findings.
None of the individuals carried the studied amino acid substitutions, which
included G2019S, and the pleomorphic pathology–associated R1441C/G/H
(172).
6.7 PINK1 mutation frequencies and clinical findings
In Paper V we performed an extensive mutational analysis of the PINK1 gene in
a total of 131 Norwegian patients with early-onset or familial late-onset PD. We
did not find any homozygous or compound heterozygous mutation carriers.
Three patients (2%) carried heterozygous mutations that were not found in any
of 350 Norwegian control individuals. The main conclusion of this study is
therefore that pathogenic PINK1 mutations are rare our population.
We cannot completely exclude the presence of unidentified mutations. For
example, mutations affecting gene expression localized in the promoter or the
introns, would not have been detected in this study. Deletions and
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multiplications of the PINK1 gene seem to be rare, and only one exonic deletion
has been reported (94). Our quantitative analysis did not detect any mutations,
but we only examined two exons and some mutations might have been missed.
However, the PINK1 gene spans only 1.8 kb of genomic sequence and
therefore most deletion and duplication mutations are likely to encompass the
entire gene, or are likely to be sufficiently small to be identified through
sequence analysis.
In addition, we identified three novel genetic variants that are probably benign
polymorphisms. Two of them were silent mutations (Arg279Arg and
Asn410Asn). The third variant was a novel exonic c.1745G>T mutation
removing the stop codon (Stop582Leu), leading to the translation of nine
additional amino acids until the next stop codon occurs. This variant was found
in one patient and two controls and has unknown pathogenic significance. We
found no association between common genetic variation in the PINK1 gene and
PD in Paper V. This result is in accordance with other studies of Finnish and
British populations (173, 174).
The frequency of PINK1 mutations was lower in our study than in some of the
previously published reports, as no patient had disease definitely caused by this
gene. There are at least two possible explanations for this finding. First, the
frequency of PINK1-associated disease varies between populations. Studies of
patients with sporadic EOP from Italy have found homozygous mutations in 2-
4% of patients (97, 99). A study of Asian patients also found homozygous
mutations in 2% of EOP patients (98). On the other hand, only one
heterozygous carrier was found in a total of 290 PD patients from Ireland (175).
Second, the mutation frequency in a study depends on the criteria used for
inclusion of patients. Patients with PINK1 mutations have a mean age of
disease onset of around 31 years (99). The mean age at onset in our study was
considerably higher: 44 years in the EOP group and 64 group in the familial PD
group. Also, the highest number of mutation carriers is found in studies of
autosomal recessive disease. Only a minority of patients included in Paper V
had evidence of autosomal recessive disease transmission.
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The clinical presentation of the three patients with heterozygous mutations was
very similar to that found in most other families and sporadic cases with PINK1
mutations (97, 100). All patients have a slowly progressive parkinsonian
syndrome; none of them showed any sign of early dementia, psychiatric
symptoms or had dystonia at disease onset. Only one of our patients has so far
received dopaminergic treatment and this patient showed an excellent and
sustained effect of levodopa-treatment. She developed severe dyskinesias,
which have been successfully treated with the implantation of an STN-
stimulator. Overall the clinical features were relatively benign and
indistinguishable from idiopathic PD.
6.8 PINK1 heterozygosity and parkinsonism
The role of single heterozygous PINK1 mutations in PD is difficult to interpret,
but there is growing evidence suggesting that heterozygous mutation carriers
might be at increased risk to develop disease. The two novel mutations found in
Paper V were absent in a large number of Norwegian control chromosomes,
making it unlikely that they are rare polymorphisms. The PINK1 transcript
encodes a protein kinase and localizes to the mitochondria (91). Both mutations
are located in the kinase domain and the affected amino acids are highly
conserved. Thus, these protein alterations may affect the kinase activity of the
protein.
Most other investigators have also found a higher frequency of heterozygous
mutations in patients compared to controls. If analyzed combined, two studies
from Italy found a significant association between PINK1 heterozygosity and
disease (5% in patients and 1% in controls, P<0.01) (99). A recent study of
PINK1 mutations in 768 patients with PD and matched controls also found a
higher frequency of heterozygous mutations in patients (1.2% vs. 0.4%) (176).
Single PINK1 variants could affect the product of the other allele (dominant
negative), act as gain-of-function mutations (dominant) or decrease protein
activity to around 50% (haploinsufficiency). In all three models, one should
observe a dominant pattern of disease transmission. It is therefore of interest
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that in one of the patients identified in Paper V, the Gly411Ser mutation seemed
to be transmitted in a pattern compatible with autosomal dominant inheritance.
A previous PET study of unaffected heterozygous PINK1 mutation carriers
showed a significant reduction in 18F-dopa uptake in comparison to controls
(101). This suggests that some mutations in heterozygous state cause a
decreased striatal dopamine storage capacity, predisposing to late-onset PD.
Interestingly, mean age at disease onset of heterozygous carriers has been
more than 10 years later than in patients with two mutations in the gene (99). In
addition, in a recent study of a large German pedigree six members with
heterozygous mutations showed mild signs of PD, although they were all
unaware of their signs (177).
An alternative explanation is that other factors act in combination with PINK1
mutations to cause disease. Digenic inheritance of EOP with mutations in both
DJ-1 and PINK1 has been reported in a Chinese family, and functional studies
in a cell model indicated that the two proteins interact (178). Genetic
interactions between PINK1 and parkin have also been reported. Loss of PINK1
in Drosophila melanogaster models lead to defects in mitochondrial function
with muscle and dopaminergic neuron degeneration that can be rescued by
parkin (103-105).
In conclusion, there is several lines of evidence indicating a role of
heterozygous PINK1 mutations in PD. However, further sequencing of large
series of cases and controls and functional studies are warranted before any
definite conclusions can be made.
70
Conclusions
From the studies presented in this thesis we have gained new and important
insights into the genetics of PD:
· First, a single Lrrk2 G2019S mutation is established as the most common
known genetic cause of PD. The mutation is present in a range of
populations and inherited from a common ancestor. Fascinatingly,
mutations in the LRRK2 gene are inherited in an autosomal dominant
fashion with reduced penetrance, as proposed by Henry Mjönes in his study
from the 1940’s.
· Second, the majority of LRRK2-associated patients are clinically
indistinguishable from typical sporadic PD. Age of disease onset is variable,
but mainly late-onset. This demonstrates that a proportion of late-onset PD
has a genetic basis.
· Third, the majority of postmortem cases with LRRK2 mutations have LBD,
as found in sporadic PD.
· Fourth, LRRK2 mutations are uncommon in other neurodegenerative
disorders than PD.
· Finally, PINK1-associated PD is rare in Norway, but heterozygous
mutations might increase the risk of developing disease. This further
highlights the role of genetics in PD.
Following the identification of LRRK2 mutations, a remarkable paradigm shift
has occurred in the field of neurodegeneration regarding the influence of
genetics on disease. It is now clear that genetics plays a much more important
role in the pathogenesis of PD than previously thought.
The remarkable advances in the genetics of parkinsonism over the last ten
years have provided substantial insights into the molecular pathways and
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disease mechanisms involved in the development and pathogenesis of the
syndrome. Mutations in the LRRK2 and PINK1 genes only explain the cause of
PD in a minority of patients. However, these findings have identified key
disease mechanisms of neurodegeneration and generated hypotheses for
studies in cell systems and animal models. It appears that sporadic PD is
heterogenous in nature, with multiple and varied causal factors acting upon a
number of biological pathways.
With improvements in DNA technology, genetic studies in large groups of
families and sporadic PD patients are possible. These ongoing studies, and the
identification of novel genes within the other PARK loci, will further enhance our
knowledge of the cause of PD and direct future research.
Hopefully, genetic research and identification of the pathways involved in the
development of PD, can pave the way for new therapeutics. Only when disease
progression can be stopped, we will have a real treatment for the disorder
James Parkinson described almost two hundred years ago.
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